Page last updated: 2024-12-08

telbivudine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID159269
CHEMBL ID374731
CHEBI ID63624
SCHEMBL ID124279
MeSH IDM0469133

Synonyms (85)

Synonym
AC-5632
AB01274717-01
CHEMBL374731
sebivo
tyzeka
ldt-600
nv-02b
telbivudine (usan/inn)
tyzeka (tn)
D06675
telbivudine ,
ldt ,
1-[(2s,4r,5s)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione
nv 02b
l-deoxythymidine
l-dt
3424-98-4
thymine, 1-(2-deoxy-.beta.-l-erythro-pentofuranosyl)-
beta-l-2'-deoxythymidine
DB01265
beta-l-thymidine
telbivudin
2'-deoxy-l-thymidine
epavudine
1-(2-deoxy-beta-l-ribofuranosyl)-5-methyluracil
thymine, 1-(2-deoxy-beta-l-erythro-pentofuranosyl)-
ldt600
nb 02b
2,4(1h,3h)-pyrimidinedione, 1-(2-deoxy-b-l-erythro-pentofuranosyl)-5-methyl-
telbivudine [usan]
1-(2-deoxy-beta-l-erythropentafuranosyl)-5-methyl-2,4(1h,3h)-pyrimidinedione
1-(2-deoxy-beta-l-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1h,3h)-dione
chebi:63624 ,
bdbm50088372
LLT ,
1-[(2r,4r,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
1-[(2s,4r,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
2,4(1h,3h)-pyrimidinedione, 1-(2-deoxy-beta-l-erythro-pentofuranosyl)-5-methyl-
telbivudine [usan:inn:ban]
unii-2oc4hkd3sf
2oc4hkd3sf ,
NCGC00346560-01
telbivudine [mart.]
telbivudine [orange book]
telbivudine [who-dd]
2,4(1h,3h)-pyrimidinedione,1-(2-deoxy-.beta.-l-erythro-pentofuranosyl)-5-methyl-
telbivudine [inn]
telbivudine [ema epar]
telbivudine [mi]
telbivudine [vandf]
1-((2s,4s,5s)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1h,3h)-dione
S1651
BRD-K15976406-001-01-7
HY-B0017
CS-1934
SCHEMBL124279
AKOS025117349
IQFYYKKMVGJFEH-CSMHCCOUSA-N
1-((2s,4r,5s)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1h,3h)-dione
AB01274717_02
1-beta-l-ribofuranosylthymine
1-[(2s,4r,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
DTXSID30187813 ,
1-[(2s,4r,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione
telbivudine, >=98% (hplc)
SW220236-1
b-l-2'-deoxy-thymidine
epavudine;l-thymidine;nv 02b
Q413621
telbivudine (sebivo, tyzeka)
AS-35209
AMY23971
EN300-123027
CCG-266887
NCGC00346560-06
beta l 2' deoxythymidine
NCGC00346560-12
telbivudina
2,4(1h,3h)-pyrimidinedione,1-(2-deoxy-beta-l-erythro-pentofuranosyl)-5-methyl-
dtxcid90110304
j05af11
telbivudinum
telbivudine (mart.)
Z1546610488
BP-58605

Research Excerpts

Overview

Telbivudine (LdT) is an anti-hepatitis B virus (HBV) drug that has been found to steadily improve renal function, but the mechanism of drug action is unclear. It has been reported to block mother-to-infant transmission.

ExcerptReferenceRelevance
"Telbivudine (LdT) is an orally L-nucleoside with potent and specific antihepatitis B virus (HBV) activity. "( Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study.
Gao, M; Li, J; Liu, J; Lu, W; Yang, X; Zhou, L, 2017
)
2.11
"Telbivudine (LdT) is an anti-hepatitis B virus (HBV) drug that has been found to steadily improve renal function, but the mechanism of drug action is unclear."( Telbivudine attenuates UUO-induced renal fibrosis via TGF-β/Smad and NF-κB signaling.
Chen, J; Li, D, 2018
)
2.64
"Telbivudine is an orally nucleoside analog with potent and specific antihepatitis B virus (HBV) activity, and it has been reported to block mother-to-infant transmission. "( Motor development delay in offspring is associated with prenatal telbivudine exposure.
Hou, M; Huang, HF; Jin, L; Miao, M; Sheng, J; Wang, H; Yang, Q; Yang, X; Yu, Y; Zhang, F; Zhou, C, 2018
)
2.16
"Telbivudine is an L-nucleoside analogue with potent antiviral activity against hepatitis B virus (HBV). "( Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B.
Ahn, SH; Han, KH; Kim, EH; Kim, SM; Lee, KH; Park, H, 2013
)
2.2
"Telbivudine is a nucleoside analogue that has been approved for the treatment of chronic hepatitis B virus (HBV) infection in adults at 600 mg/day. "( Phase I, open-label, single-dose study to evaluate the pharmacokinetics and safety of telbivudine in children and adolescents with chronic hepatitis B.
Bosheva, M; Ke, J; Praestgaard, J; Qi, Y; Stein, DS; Uy, G, 2013
)
2.06
"Telbivudine seemed to be a candidate for exclusive anti-HBV therapy because it exerts no significant in vitro activity against HIV."( In vivo antiviral activity of telbivudine against HIV-1: a case report.
Bonadies, G; Borgia, G; Borrelli, F; Buonomo, AR; Carleo, MA; Gentile, I; Portella, G, 2013
)
1.4
"Telbivudine is an effective and safe drug for preventing intrauterine transmission of HBV."( Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis.
Chen, YP; Hocher, B; Huang, SM; Li, J; Liang, XJ; Liu, ZW; Lu, YP; Xiao, XM, 2014
)
3.29
"Telbivudine is a relatively novel oral nucleoside analogue with favourable efficacy and tolerability in treatment-naïve chronic hepatitis B virus (HBV) infection, but its data in kidney transplant recipients (KTRs) was lacking. "( Use of telbivudine in kidney transplant recipients with chronic hepatitis B virus infection: A preliminary experience.
Chan, TM; Yap, DY, 2016
)
2.33
"Telbivudine is an L-nucleoside that is structurally related to lamivudine and has recently been approved for use in patients with chronic HBV infection."( Telbivudine in the treatment of chronic hepatitis B.
Nash, K, 2009
)
2.52
"Telbivudine is a new antiviral agent joining the armamentarium against HBV. "( Telbivudine in the treatment of chronic hepatitis B.
Nash, K, 2009
)
3.24
"Telbivudine is a new nucleoside analog indicated for the treatment of chronic hepatitis B infection. "( Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment.
Farrell, C; Ke, J; Mayers, DL; Pentikis, HS; Sallas, WM; Zhou, XJ, 2009
)
2.08
"Telbivudine is a potent inhibitor of hepatitis B virus (HBV) replication without anti-HIV type-1 (HIV-1) activity demonstrated in vitro; however, very few clinical data on HIV-1-infected patients are available at present. "( Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy.
Balotta, C; Caramma, I; Cesari, M; De Maddalena, C; Galli, M; Lai, A; Milazzo, L; Violin, M, 2009
)
3.24
"Telbivudine is an orally bioavailable L-nucleoside with potent and specific anti-hepatitis B virus activity. "( Telbivudine preserves T-helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis.
Chen, T; Guo, W; Lu, YL; Luo, XP; Ning, Q; Wang, HW; Wang, XJ; Wu, ZG; Yan, WM; Yang, XJ; Zou, Y, 2010
)
3.25
"Telbivudine is a potent antiviral that provides effective and sustained viral suppression in patients with compensated CHB."( Telbivudine: a review of its use in compensated chronic hepatitis B.
Keam, SJ; McKeage, K, 2010
)
2.52
"Telbivudine is a synthetic thymidine nucleoside analogue with activity against HBV."( The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis.
Chen, HZ; Deng, M; Gao, S; Ruan, B; Wang, B; Yang, SG; Zhou, X, 2012
)
1.45
"Telbivudine is a novel, orally administered nucleoside analog under development for use in the treatment of chronic hepatitis B. "( Telbivudine: a novel nucleoside analog for chronic hepatitis B.
Kim, JW; Louie, SG; Park, SH, 2006
)
3.22
"Telbivudine is a novel oral nucleoside analog effective in the treatment of chronic hepatitis B infection."( Telbivudine: a novel nucleoside analog for chronic hepatitis B.
Kim, JW; Louie, SG; Park, SH, 2006
)
3.22
"Telbivudine is a novel, orally administered nucleoside analogue for use in the treatment of chronic hepatitis B."( Telbivudine: a new treatment for chronic hepatitis B.
Amarapurkar, DN, 2007
)
2.5
"Telbivudine is an L-nucleoside analogue with potent antiviral activity against hepatitis B virus (HBV). "( [The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].
Ahn, SH; Cho, M; Choi, HS; Han, JY; Hwang, SG; Kim, BS; Kim, DJ; Kim, YS; Moon, YM; Rim, KS, 2007
)
2.08
"Telbivudine (LdT) is an L-nucleoside that is structurally related to lamivudine. "( Telbivudine for the management of chronic hepatitis B virus infection.
Matthews, SJ, 2007
)
3.23
"Telbivudine is a novel nucleoside drug recently approved for the treatment of patients with chronic hepatitis B. "( Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B.
Bridges, EG; Luo, S; Selden, JR, 2008
)
2.08

Effects

Telbivudine (LdT) has demonstrated potent antiviral activity in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B patients (CHB), but data on its efficacy in NA-experienced patients are limited. The drug has been reported to be associated with myopathy and neuropathy, particularly when used in combination with pegylated interferon.

ExcerptReferenceRelevance
"Telbivudine has a resistance rate lower than that of LAM and higher than that of entecavir or tenofovir."( Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses.
Hann, HW, 2010
)
2.52
"Telbivudine (LdT) has demonstrated potent antiviral activity in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B patients (CHB), but data on its efficacy in NA-experienced patients are limited. "( Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.
Bai, XF; Li, Y; Lian, JQ; Wang, JP; Zhang, Y, 2013
)
2.21
"Telbivudine treatment has efficacy and safety on MTCT interruption during late pregnancy. "( Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis.
Hu, HD; Liu, JY; Liu, MH; Ren, H; Sheng, YJ; Zhang, QF,
)
1.95
"Telbivudine therapy has been proved to inhibit HBV replication effectively and to improve clinical outcome of chronic hepatitis B (CHB)."( Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic hepatitis B.
Bai, X; Hao, C; Jia, Z; Kang, W; Lian, J; Ma, L; Peng, M; Wang, J; Xie, Y; Zhou, Y, 2013
)
1.39
"Telbivudine has superior efficacy compared to lamivudine and adefovir."( A review of telbivudine for the management of chronic hepatitis B virus infection.
Chan, HL; Lui, YY, 2008
)
1.45
"Telbivudine has also been reported to be associated with myopathy and neuropathy, particularly when used in combination with pegylated interferon."( Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B.
Fleischer, RD; Lok, AS, 2009
)
1.07
"Telbivudine has a resistance rate lower than that of LAM and higher than that of entecavir or tenofovir."( Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses.
Hann, HW, 2010
)
2.52
"Telbivudine treatment has significantly improved the clinical outcome of chronic HBV infection."( Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B.
Bai, XF; Li, Y; Lian, JQ; Nan, XP; Peng, MJ; Su, WJ; Sun, RL; Wang, JP; Yu, HT; Zhang, Y, 2012
)
1.1
"Telbivudine has potent antiviral activity against hepatitis B virus (HBV) in vitro and in the woodchuck model and has a promising preclinical safety profile."( A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection.
Brown, NA; Chao, GC; Lai, CL; Lee, YM; Lim, SG; Lloyd, DM; Myers, MW; Yuen, MF; Zhou, XJ, 2004
)
1.31
"Telbivudine has been generally well tolerated, with low adverse effect profile, and at its effective dose, no dose-limiting toxicity has been observed."( Telbivudine: a novel nucleoside analog for chronic hepatitis B.
Kim, JW; Louie, SG; Park, SH, 2006
)
2.5
"Telbivudine has demonstrated potent activity against hepatitis B with a significantly higher rate of response and superior viral suppression compared with lamivudine, the standard treatment."( Telbivudine: a new treatment for chronic hepatitis B.
Amarapurkar, DN, 2007
)
2.5

Actions

Telbivudine can cause severe side effects, including myositis, neuritis, rhabdomyolysis, and lactic acidosis. It appears to cause accelerated muscle toxicity if given to patients who already have muscle damage.

ExcerptReferenceRelevance
"Telbivudine can cause severe side effects, including myositis, neuritis, rhabdomyolysis, and lactic acidosis. "( Rhabdomyolysis, lactic acidosis, and multiple organ failure during telbivudine treatment for hepatitis B: a case report and review of the literature.
Chen, Z; Deng, M; Deng, Q; Deng, X; Li, D; Qiu, X; Yu, Z; Zheng, J, 2017
)
2.13
"Telbivudine resulted in lower HBsAg and HBV DNA seroprevalence in newborns and infants."( Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis.
Hu, HD; Liu, JY; Liu, MH; Ren, H; Sheng, YJ; Zhang, QF,
)
1.23
"Telbivudine appears to cause accelerated muscle toxicity if given to patients who already have muscle damage. "( Myotoxicity of telbivudine in pre-existing muscle damage.
Ay, L; Finsterer, J, 2010
)
2.16

Treatment

Telbivudine treatment reduced sACE2 concentrations, which could potentially reduce the infection risk of SARS-CoV-2. The drug inhibited mitochondrial complex I and IV expression, impairing the oxidative phosphorylation function of the respiratory chain. TelbivUDine treatment has efficacy and safety on MTCT interruption during late pregnancy.

ExcerptReferenceRelevance
"Telbivudine treatment reduced sACE2 concentrations, which could potentially reduce the infection risk of SARS-CoV-2."( Reduction of ACE2 Serum Concentrations by Telbivudine in Chronic Hepatitis B Patients.
Hsu, CW; Huang, YH; Lin, YH; Yeh, CT, 2023
)
2.62
"Telbivudine treatment significantly inhibited mitochondrial complex I and IV expression, impairing the oxidative phosphorylation function of the respiratory chain."( Insights into the mechanisms of telbivudine-induced myopathy associated with mitochondrial dysfunction.
Li, Z; Lin, P; Wu, W; Yan, C; Yu, W; Zhao, D, 2023
)
1.92
"Telbivudine treatment resulted in increased levels of serum KLK8 protein. "( Increase of Serum Kallikrein-8 Level After Long-term Telbivudine Treatment.
Lin, CL; Pan, TL; Wang, HE; Yeh, CT,
)
1.82
"Telbivudine treatment has efficacy and safety on MTCT interruption during late pregnancy. "( Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis.
Hu, HD; Liu, JY; Liu, MH; Ren, H; Sheng, YJ; Zhang, QF,
)
1.95
"Telbivudine treatment starting from the 12th week of gestation or from the 20-28th week of gestation can significantly decrease the serum HBV DNA level in peripheral blood of pregnant women with high viremia and reduce the infection rate of HBV in their neonates."( [Predictive value of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women with high viremia].
Hao, A; Li, M; Liu, W; Ma, L; Song, M; Sun, W; Xin, Y, 2015
)
2.18
"Telbivudine combination treatment with adefovir was more effective than telbivudine monotherapy and elicited a low drug resistance rate in nucleos(t)idenaive chronic hepatitis B patients with high-level HBV load and HBeAg-positivity. "( [Efficacy and safety of telbivudine alone and combined with adefovir for the treatment of nucleos(t)ide-naive chronic hepatitis B in patients with high-level hepatitis B virus load].
Dang, B; Kang, W; Liu, Q; Sun, Y; Wang, C; Yao, N; Yu, Z; Zhao, K, 2015
)
2.17
"The telbivudine treatment was initiated at gestation week 26 as oral dosing of 600 mg/d and continued until 1 month after the birth.Women in the control group had not gotten any antiviral drug treatment."( [The safety of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women after discontinuation].
Deng, Y; Hu, P; Kang, J; Wu, W; Yang, Y; Zeng, W; Zhang, D, 2015
)
1.25
"The telbivudine-treated women showed a significant decrease in HBV DNA levels prior to delivery, as well as significantly decreased prenatal HBV DNA levels (>2 logl0). "( [The safety of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women after discontinuation].
Deng, Y; Hu, P; Kang, J; Wu, W; Yang, Y; Zeng, W; Zhang, D, 2015
)
1.33
"Telbivudine treatment, whether short term or long term, is associated with higher HBeAg seroconversion compared with the other NAs."( HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.
Cao, L; Xing, T; Xu, H; Ye, M, 2017
)
1.18
"Telbivudine-treated HBeAg-negative patients showed higher rates of nondetectable viremia compared with lamivudine at 82.0% versus 56.7% (P < .001) and less resistance at 10.8% versus 25.9% (P < .001)."( 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
Albanis, E; Brown, NA; Bzowej, N; Cakaloglu, Y; Chen, Y; Galil, K; Gane, E; Han, SH; Heathcote, EJ; Hwang, SG; Lai, CL; Leung, N; Liaw, YF; Manns, M; Naoumov, NV; Niu, J; Papatheodoridis, G; Tong, MJ; Wang, Y; Zeuzem, S, 2009
)
1.37
"Telbivudine treatment reduces HBV replication and the proportion of peripheral blood Tregs. "( [The effect of telbivudine on peripheral blood CD4+CD25+ regulatory T cells and its significance in patients with chronic hepatitis B].
Chen, M; Pan, XC; Yang, F, 2008
)
2.14
"Telbivudine treatment can block intrauterine infection in pregnant chronic hepatitis B patients."( [Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients].
Wang, L; Zhang, LJ, 2009
)
2.07
"Telbivudine treatment results in suppression of HBV and high HBeAg seroconversion, and improvement of Child-Pugh score in the patients with liver cirrhosis."( [Clinical antiviral effects of telbivudine in patients with chronic hepatitis B].
Guo, HH; Ji, SW; Jiao, J; Li, Y; Siqingtu, NL; Wang, JB; Xu, Y; Zhang, YG; Zhao, P; Zhou, CY, 2010
)
2.09
"Telbivudine treatment progressively reduced serum HBsAg levels (mean ± SD) from baseline (3.8 ± 0.6 log₁₀ IU/mL) to treatment week 24 (3.4 ± 0.7 log₁₀ IU/mL), treatment year 1 (3.3 ± 0.8 log₁₀ IU/mL), and treatment year 3 (3.0 ± 1.4 log₁₀ IU/mL) (P <0.0001)."( Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.
Bao, W; Goodman, ZD; Jung, M; Lopez, P; Manns, MP; Naoumov, NV; Riva, A; Wedemeyer, H; Wursthorn, K, 2010
)
1.32
"In Telbivudine-treated group, the HBeAg decline is more than 2 log at week 24, HBeAg decline is more than 1 log at week 12 and the HBeAg baseline were independent factors correlated to HBeAg seroconversion rates at week 52 by Binary Logistic analysis, and also in entecavir-treated group the HBeAg decline is more than 2 log at week 24, HBeAg decline is more than 2 log at week 36 and the HBeAg decline is more than 2 log at week 12 were independent factors correlated to HBeAg seroconversion rates at week 52."( [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients].
Chen, R; Chen, WL; Chen, XF; Chen, XP; Huang, J; Luo, XD; Ma, XJ, 2011
)
1.12
"All telbivudine treated subjects were registered in the Antiretroviral Pregnancy Registry."( A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection.
Bai, SF; Cao, MK; Fang, ZX; Han, GR; Jiang, HX; Tang, X; Wang, CM; Wang, GJ; Yue, X; Zhao, W, 2011
)
1.09
"Telbivudine treatment was associated with a marked reduction in serum HBV DNA and hepatitis B e antigen (HBeAg) levels and normalization of elevated ALT levels before delivery. "( A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection.
Bai, SF; Cao, MK; Fang, ZX; Han, GR; Jiang, HX; Tang, X; Wang, CM; Wang, GJ; Yue, X; Zhao, W, 2011
)
2.05
"Telbivudine treatment has significantly improved the clinical outcome of chronic HBV infection."( Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B.
Bai, XF; Li, Y; Lian, JQ; Nan, XP; Peng, MJ; Su, WJ; Sun, RL; Wang, JP; Yu, HT; Zhang, Y, 2012
)
1.1
"Telbivudine-treated mothers had no virologic breakthrough (HBV DNA >1 log(10) increase from <500 copies/mL) or discontinuations from adverse events."( Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B.
Cao, MK; Han, GR; Jiang, HX; Pan, CQ; Wang, CM; Wang, GJ; Yue, X; Zhao, W, 2012
)
2.54
"All telbivudine treated subjects were registered in the Antiretroviral Pregnancy Registry."( [Efficacy and safety of telbivudine in pregnant women to prevent perinatal transmission of hepatitis B virus].
Han, GR; Jiang, HX; Kan, NY; Wang, CM; Wang, GJ; Wu, MM; Yue, X, 2012
)
1.17
"Telbivudine treatment was an independent predictive factor for HBV DNA <300 copies/mL and ALT normalization (P = 0.037)."( Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis.
Avila, C; Bao, W; Chan, HL; Chen, YC; Choudhuri, G; Chutaputti, A; Gane, EJ; Hwang, SG; Piratvisuth, T; Prabhakar, B; Safadi, R; Sarin, SK; Suh, DJ; Tanwandee, T; Trylesinski, A; Yurdaydin, C, 2012
)
1.35
"Telbivudine treatment effectively and safely prevents mother-to-child transmission of HBV from chronically infected mothers with a high degree of infectivity late in pregnancy."( [Efficacy and safety of telbivudine treatment to block mother-to-child transmission of hepatitis B virus: a meta-analysis].
Chen, Y; Liu, XX; Wang, LJ; Wu, YP; Xu, HX; Xu, YF; Yu, YX, 2012
)
2.13

Toxicity

Telbivudine therapy is generally safe and well tolerated among adult Indonesian patients with chronic hepatitis B. All adverse events were mild, and none occurred in more than one patient.

ExcerptReferenceRelevance
" Telbivudine was well tolerated in the studied dose range in healthy Chinese subjects, with no pattern of dose-related clinical or laboratory adverse events."( Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects.
Brown, NA; Chao, GC; Hu, P; Jiang, J; Pietropaolo, K; Wang, H; Zhou, XJ, 2006
)
1.49
"Successful treatment of chronic hepatitis B (CHB) often requires long-term oral nucleoside/nucleotide agents which can be associated with viral resistance, patient non-compliance and adverse effects."( Safety evaluation of telbivudine.
But, DY; Fung, J; Lai, CL; Yuen, MF, 2010
)
0.68
" Viral resistance, characteristic adverse effects including elevation in creatine kinase and peripheral neuropathy in telbivudine treatment are reviewed."( Safety evaluation of telbivudine.
But, DY; Fung, J; Lai, CL; Yuen, MF, 2010
)
0.89
" Creatine kinase elevation is not a good predictor of muscle-related adverse effects with nucleoside/nucleotide analogs."( Safety evaluation of telbivudine.
But, DY; Fung, J; Lai, CL; Yuen, MF, 2010
)
0.68
" No serious adverse events were noted in the telbivudine-treated mothers or their infants."( A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection.
Bai, SF; Cao, MK; Fang, ZX; Han, GR; Jiang, HX; Tang, X; Wang, CM; Wang, GJ; Yue, X; Zhao, W, 2011
)
0.87
" No telbivudine discontinuations occurred from adverse events, and no congenital deformities were observed in the infants delivered to telbivudine-treated mothers."( [Efficacy and safety of telbivudine in pregnant women to prevent perinatal transmission of hepatitis B virus].
Han, GR; Jiang, HX; Kan, NY; Wang, CM; Wang, GJ; Wu, MM; Yue, X, 2012
)
1.24
"Orally administered nucleus(t)ide analogues (NA) have brought about a simple, safe and effective therapeutic approach for chronic hepatitis B (CHB)."( Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy.
Cai, H; Liu, M; Yi, W, 2013
)
0.79
" Most adverse events were mild or moderate in severity and transient."( Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.
Bao, W; Chan, HL; Gane, EJ; Hou, J; Jia, J; Liaw, YF; Naoumov, NV; Niu, J; Papatheodoridis, G; Thongsawat, S; Trylesinski, A; Wan, M; Wang, Y, 2013
)
0.66
" Telbivudine was well tolerated; all adverse events were mild, and none occurred in more than one patient."( Phase I, open-label, single-dose study to evaluate the pharmacokinetics and safety of telbivudine in children and adolescents with chronic hepatitis B.
Bosheva, M; Ke, J; Praestgaard, J; Qi, Y; Stein, DS; Uy, G, 2013
)
1.52
" The primary end-point was patient safety (adverse event or serious adverse events); while the secondary end-points were HBeAg seroconversion, changes of serum HBV DNA levels and serum ALT normalization."( An observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis B.
Lesmana, LA; Sulaiman, A, 2014
)
0.64
" Adverse events were reported in 7 (4."( An observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis B.
Lesmana, LA; Sulaiman, A, 2014
)
0.64
" At treatment weeks 12, 24, 48?, 96, 144, 192, and 240 patients were tested for hepatitis B virus (HBV) DNA, HBeAg seroconversion and ALT normalization time; in addition, the incidence and type of adverse drug reactions were recorded."( [Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients].
Chang, L; Du, Y; Jia, T; Li, H; Li, W; Liu, L; Liu, Y; Peng, D, 2014
)
0.68
"This retrospective investigation carried out in Guangdong Province indicated that not only are anti-HBV drugs efficacious for blocking vertical transmission of HBV but also are safe for both mothers and infants when taken by fathers or mothers during the reproduction phases of insemination and pregnancy."( [Retrospective analysis of the efficacy and safety of anti-hepatitis B virus drugs taken during pregnancy in women from the Guangdong Province].
Chen, X; Gao, W; Li, D; Peng, J; Wen, F; Xia, J; Xu, C; Xu, M; Yao, Z, 2014
)
0.4
" LdT treatment was safe for mothers and infants, and no congenital deformities were reported."( Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection.
Ding, Y; Han, GR; Jiang, HX; Wang, CM; Wang, GJ; Yang, YF; Yue, X, 2015
)
0.73
"1% reduction in serum ALT with no significant adverse effects."( ALT CHANGES AND ADVERSE EVENTS OF TELBIVUDINE IN HEPATITIS-B PATIENTS-AN EXPERIENCE OF 11 PATIENTS.
Ahson, S; Ali, Z; Khan, MA; Maheshwary, N; Zara, U,
)
0.41
" The telbivudine treatment group had no case of maternal or fetal adverse reaction or of congenital malformation."( [The safety of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women after discontinuation].
Deng, Y; Hu, P; Kang, J; Wu, W; Yang, Y; Zeng, W; Zhang, D, 2015
)
1.28
"This study indicates that newer antivirals are effective and safe in HTR with CHB."( Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients.
Andini, R; Durante-Mangoni, E; Falco, E; Iossa, D; Maiello, C; Parrella, A; Ragone, E; Utili, R; Vitrone, M; Zampino, R, 2016
)
0.69
" The immediate drug withdrawal after childbirth is safe for the mother."( [Telbivudine for prevention of perinatal transmission in pregnant women infected with hepatitis B virus in immune-tolerant phase: a study of efficacy and safety of drug withdrawal].
Bai, H; Ding, Y; Dou, XG; Fan, YX; Han, C; Li, BJ; Li, YW; Sheng, QJ; Zhang, C, 2016
)
1.34
" Serious adverse events requiring hospitalization occurred in 20 infants (9."( Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy.
Ding, Y; Han, GR; Jiang, HX; Wang, CM; Wang, GJ; Yue, X; Zhao, W; Zhou, L, 2017
)
0.74
" In addition, adverse events regarding infants at delivery and HBV vaccination outcomes were recorded."( Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up.
Bai, L; Liu, K; Shang, J; Tang, H; Wang, CC; Wen, Q, 2017
)
0.77
"Treatment with lamivudine or telbivudine for active CHB in early pregnancy appears to be safe and effective for controlling maternal disease as well as interrupting MTCT."( Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B.
Bai, Y; Cai, H; He, T; Jia, J; Liu, M; Ou, X; Yi, W, 2018
)
1.05
"SOD1 misfolding, toxic gain of function, and spread are proposed as a pathological basis of amyotrophic lateral sclerosis (ALS), but the nature of SOD1 toxicity has been difficult to elucidate."( Tryptophan 32 mediates SOD1 toxicity in a in vivo motor neuron model of ALS and is a promising target for small molecule therapeutics.
Allison, WT; Blinov, N; Bratvold, J; Cashman, NR; DuVal, MG; Hinge, VK; Kanyo, R; Kovalenko, A; Pokrishevsky, E; Snyder, N, 2019
)
0.51
" Entecavir and tenofovir were safe and well tolerated, while treatment with telbivudine was associated with development of myopathy in 13% of cases."( Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B.
Abdurakhmanov, DT; Ibragimov, EK; Moiseev, SV; Nikulkina, EN; Odintsov, AV; Panevkina, SV; Rozina, TP; Tanaschuk, EL, 2019
)
0.74
" However, less attention has been put on their adverse events."( Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs.
Ji, J; Jia, Y; Shen, Y; Xun, P; Zhou, J, 2019
)
0.51
" Poisson-prior-based Bayesian NMA was performed to synthesize both direct and indirect evidence with reporting hazard ratios (HRs) and 95% credible intervals (CrIs) for serious adverse events (SAEs) and hepatic/renal impairments."( Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs.
Ji, J; Jia, Y; Shen, Y; Xun, P; Zhou, J, 2019
)
0.51
" However, gastrointestinal adverse effects (vomiting) occurred more frequently in TDF-treated than LdT-treated patients (6."( Clinical efficacy and safety in telbivudine- or tenofovir-treated hepatitis B e antigen-positive pregnant women.
Chen, K; Deng, H; Gao, H; Jiao, Q; Lei, Y; Li, H; Liang, S; Lin, L; Liu, H; Shi, Y; Xu, M; Zhuo, L, 2020
)
0.84
"This study revealed that the clinical efficacy in LdT- or TDF-treated HBeAg-positive Chinese pregnant women is similar, and gastrointestinal adverse effects occurred more frequently in TDF-treated patients."( Clinical efficacy and safety in telbivudine- or tenofovir-treated hepatitis B e antigen-positive pregnant women.
Chen, K; Deng, H; Gao, H; Jiao, Q; Lei, Y; Li, H; Liang, S; Lin, L; Liu, H; Shi, Y; Xu, M; Zhuo, L, 2020
)
0.84
" No cases of renal injury or other obstetric adverse events occurred in either group of women."( Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancy.
Bai, L; Liu, H; M Ise, R; Shang, J; Tang, H; Tu, Y; Wen, Q, 2021
)
0.62
" However, no serious adverse events were observed in infants and mothers of all groups."( Comparison of the efficacy and safety of tenofovir and telbivudine in interrupting mother-to-child transmission of hepatitis B virus.
Chen, L; Chen, X; Dai, E; Li, C; Li, S; Lv, X; Zhao, Z; Zhu, B, 2021
)
0.87
" All LdT-treated mothers were well tolerated and no LdT-related adverse events in infants were reported."( Efficacy and Long-term Safety of Telbivudine Usage During Second or Third Trimester in Hepatitis B Surface Antigen Positive Mothers With High Viral Load: A 10-year Prospective Study.
Chen, C; Han, G; Jiang, H; Ye, X; Zhou, G, 2023
)
1.19
" LdT treatment during pregnancy is safe for both mothers and infants in the long term."( Efficacy and Long-term Safety of Telbivudine Usage During Second or Third Trimester in Hepatitis B Surface Antigen Positive Mothers With High Viral Load: A 10-year Prospective Study.
Chen, C; Han, G; Jiang, H; Ye, X; Zhou, G, 2023
)
1.19

Pharmacokinetics

Oral absorption of telbivudine as measured by maximum plasma concentration (Cmax), time to reach Cmax (Tmax), and area under the plasma concentration-time curve (AUC(0-t) and AUC( 0-infinity) was not altered by food intake immediately before oral dosing. Subjects were administered a single oral dose of 600 mg telbvudine. Blood samples were collected over a 48-h interval for pharmacokinetic analyses.

ExcerptReferenceRelevance
" Oral absorption of telbivudine as measured by maximum plasma concentration (Cmax), time to reach Cmax (Tmax), and area under the plasma concentration-time curve (AUC(0-t) and AUC(0-infinity)) was not altered by food intake immediately before oral dosing."( Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects.
Brown, NA; Chao, GC; Lloyd, DM; Zhou, XJ, 2006
)
0.91
" Pharmacokinetic and pharmacodynamic analyses by using maximum-effect modeling established a quantitative relationship between a reduction in serum HBV DNA levels and parameters of drug exposure, in particular, the steady-state C(max) and AUC(0-t)."( Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications.
Brown, NA; Chao, GC; Lai, CL; Lim, SG; Lloyd, DM; Zhou, XJ, 2006
)
0.66
" The subjects were administered a single oral dose of 600 mg telbivudine, and blood samples were collected over a 48-h interval for pharmacokinetic analyses."( Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment.
Alcorn, HW; Brown, NA; Chao, GC; Dubuc Patrick, G; Marbury, TC; Smith, WB; Zhou, XJ, 2006
)
0.9
"5 hours, plasma disposition of the drug was biphasic with a mean terminal half-life ranging from 39."( Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects.
Brown, NA; Chao, GC; Hu, P; Jiang, J; Pietropaolo, K; Wang, H; Zhou, XJ, 2006
)
0.58
"To evaluate the pharmacokinetic profile of telbivudine in healthy Chinese subjects after oral administration of single and multiple doses."( [Study on the pharmacokinetic profile of telbivudine].
Brown, NA; Hu, P; Jiang, J; Shen, K; Wang, HY; Zhou, XJ, 2006
)
0.86
" Pharmacokinetic parameters were calculated by using the non-compartmental approach."( [Study on the pharmacokinetic profile of telbivudine].
Brown, NA; Hu, P; Jiang, J; Shen, K; Wang, HY; Zhou, XJ, 2006
)
0.6
" Subjects received a single oral dose of telbivudine at 600 mg (normal function and mild impairment), 400 mg (moderate impairment), or 200 mg (severe impairment and ESRD); plasma and/or urine samples were collected over a 48-h period for pharmacokinetic analyses."( Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
Brown, NA; Chao, GC; Dubuc-Patrick, G; Marbury, TC; Smith, WB; Swan, S; Zhou, XJ, 2007
)
0.93
" A population pharmacokinetic model was developed based on data pooled from 16 early phase studies in 363 healthy participants and patients."( Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment.
Farrell, C; Ke, J; Mayers, DL; Pentikis, HS; Sallas, WM; Zhou, XJ, 2009
)
0.64
" Eligible patients were enrolled sequentially from older to younger groups, with evaluation of safety and available pharmacokinetic data after each stratum."( Phase I, open-label, single-dose study to evaluate the pharmacokinetics and safety of telbivudine in children and adolescents with chronic hepatitis B.
Bosheva, M; Ke, J; Praestgaard, J; Qi, Y; Stein, DS; Uy, G, 2013
)
0.61

Compound-Compound Interactions

Two phase I studies were conducted to assess the plasma pharmacokinetics of telbivudine and potential drug-drug interactions. The HepAD38 cell line expresses wild-type HBV, and a real-time PCR assay.

ExcerptReferenceRelevance
"Two phase I studies were conducted to assess the plasma pharmacokinetics of telbivudine and potential drug-drug interactions between telbivudine (200 or 600 mg/day) and lamivudine (100 mg/day) or adefovir dipivoxil (10 mg/day) in healthy subjects."( Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil.
Brown, NA; Chao, GC; Fielman, BA; Lloyd, DM; Zhou, XJ, 2006
)
0.89
" We investigated the activity of clevudine (CLV) in combination with other nucleoside/nucleotide analogues to determine if these combinations were compatible in vitro."( Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.
Bao, H; Furman, PA; Korba, B; Micolochick Steuer, HM; Murakami, E; Niu, C; Tolstykh, T, 2010
)
0.36
"Using the HepAD38 cell line, which expresses wild-type HBV, and a real-time PCR assay, we tested the anti-HBV activity of CLV in combination with entecavir, lamivudine, adefovir, tenofovir and telbivudine (TBV)."( Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.
Bao, H; Furman, PA; Korba, B; Micolochick Steuer, HM; Murakami, E; Niu, C; Tolstykh, T, 2010
)
0.55
"When CLV was combined with entecavir, lamivudine, adefovir or tenofovir, a synergistic antiviral effect was observed; however, the combination of CLV and TBV gave an antagonistic antiviral response."( Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.
Bao, H; Furman, PA; Korba, B; Micolochick Steuer, HM; Murakami, E; Niu, C; Tolstykh, T, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
" A final model was built with identified covariates, including creatinine clearance on plasma clearance, dose and race on bioavailability fraction, and body weight on central volume of distribution."( Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment.
Farrell, C; Ke, J; Mayers, DL; Pentikis, HS; Sallas, WM; Zhou, XJ, 2009
)
0.64
"Telbivudine is an orally bioavailable L-nucleoside with potent and specific anti-hepatitis B virus activity."( Telbivudine preserves T-helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis.
Chen, T; Guo, W; Lu, YL; Luo, XP; Ning, Q; Wang, HW; Wang, XJ; Wu, ZG; Yan, WM; Yang, XJ; Zou, Y, 2010
)
3.25
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The mean steady-state C(max) and area under the plasma concentration-time curve over the dosing interval of telbivudine 600 mg were 3. Axonopathy in the sciatic nerves and in the spinal cords of monkeys dosed at 1,000 mg/kg/day observed in a 9-month study was considered equivocal.

ExcerptRelevanceReference
" This placebo-controlled dose-escalation trial investigated 6 telbivudine daily dosing levels (25, 50, 100, 200, 400, and 800 mg/d); treatment was given for 4 weeks, with 12 weeks' follow-up."( A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection.
Brown, NA; Chao, GC; Lai, CL; Lee, YM; Lim, SG; Lloyd, DM; Myers, MW; Yuen, MF; Zhou, XJ, 2004
)
0.83
" The Phase I clinical study demonstrated that end-of-treatment virological response rates were better for telbivudine recipients at multiple dosing levels as compared with placebo patients."( Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B.
Han, SH, 2005
)
1.98
"To review available literature on the pharmacology, pharmacokinetics, dosing and administration, efficacy, and safety of the antiviral nucleoside analog telbivudine."( Telbivudine: a novel nucleoside analog for chronic hepatitis B.
Kim, JW; Louie, SG; Park, SH, 2006
)
1.97
" Steady state was reached after daily dosing for 5 to 7 days."( Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil.
Brown, NA; Chao, GC; Fielman, BA; Lloyd, DM; Zhou, XJ, 2006
)
0.66
"Forty-two healthy adult male and female subjects 18-40 years of age were randomized into four telbivudine dosing groups of 200 mg, 400 mg, 600 mg and 800 mg."( [Study on the pharmacokinetic profile of telbivudine].
Brown, NA; Hu, P; Jiang, J; Shen, K; Wang, HY; Zhou, XJ, 2006
)
0.82
" The incidence of HCC correlated with serum HBV DNA level at entry in a dose-response relationship."( Active antiviral therapy for chronic hepatitis B and hepatocellular carcinoma.
Hann, HW, 2008
)
0.35
" Axonopathy in the sciatic nerves and in the spinal cords of monkeys dosed at 1,000 mg/kg/day observed in a 9-month study was considered equivocal, as the role of telbivudine in the injury could not be determined."( Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B.
Bridges, EG; Luo, S; Selden, JR, 2008
)
0.83
" The final model was applied to simulate steady-state exposure for patients with impaired renal function for various dosing regimens."( Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment.
Farrell, C; Ke, J; Mayers, DL; Pentikis, HS; Sallas, WM; Zhou, XJ, 2009
)
0.64
"NAs are cleared by kidneys and their dosage should be adjusted in patients with creatinine clearance <50 mL/min."( Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
Cholongitas, E; Papatheodoridis, G; Pipili, C, 2014
)
0.4
" Antiviral treatments were withdrawn in patients who met all of the following 7 criteria: (i) no clinical and histologic evidence of cirrhosis, (ii) normal liver biochemistry, (iii) negative for both HBV DNA and hepatitis B envelope antigen (HBeAg), (iv) no resistance to antiviral agent, (v) antiviral therapy > 9 months, (vi) maintenance dosage of immunosuppressant for > 3 months, and (vii) no history of acute rejection during recent 6 months."( Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
Cho, JH; Choi, JY; Huh, S; Kang, YJ; Kim, CD; Kim, HK; Kim, JS; Kim, YL; Kwon, O; Lim, JH; Park, GY; Park, SH, 2014
)
0.4
" The telbivudine treatment was initiated at gestation week 26 as oral dosing of 600 mg/d and continued until 1 month after the birth."( [The safety of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women after discontinuation].
Deng, Y; Hu, P; Kang, J; Wu, W; Yang, Y; Zeng, W; Zhang, D, 2015
)
1.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitorA DNA polymerase inhibitor that interferes with the activity of reverse transcriptase, EC 2.7.7.49, a viral DNA polymerase enzyme that retroviruses need in order to reproduce.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyrimidine 2'-deoxyribonucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency9.30900.001310.157742.8575AID1259252; AID1259253; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)IC50 (µMol)713.90000.00032.63119.0000AID1207775
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Potassium voltage-gated channel subfamily E member 1Homo sapiens (human)IC50 (µMol)251.18900.12004.048010.0000AID1207389
Potassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)IC50 (µMol)251.18900.12004.048010.0000AID1207389
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)IC50 (µMol)713.90000.00032.59559.0000AID1207775
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)81,750.43510.00091.901410.0000AID1207483; AID1207543
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)IC50 (µMol)713.90000.00032.63119.0000AID1207775
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)713.90000.00032.25459.6000AID1207775
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)3,162.28000.00033.64849.2000AID1207329
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Capsid protein Hepatitis B virusEC50 (µMol)0.81940.00020.26030.8194AID1363957
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (168)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
epithelial cell maturationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
sensory perception of soundPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
male gonad developmentPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
vestibular nucleus developmentPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
secretory granule organizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cellular response to cAMPPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cellular response to acidic pHPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cellular response to light stimulusPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cardiac muscle cell action potential involved in contractionPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cardiac muscle cell contractionPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
negative regulation of protein targeting to membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
negative regulation of delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
gastrin-induced gastric acid secretionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
glucose metabolic processPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
heart developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
sensory perception of soundPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
rhythmic behaviorPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of heart contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of blood pressurePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
positive regulation of heart ratePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
iodide transportPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
erythrocyte differentiationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
intracellular chloride ion homeostasisPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
response to insulinPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
social behaviorPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
corticosterone secretionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
inner ear morphogenesisPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
inner ear developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
intestinal absorptionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of soundPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
auditory receptor cell developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
positive regulation of cardiac muscle contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of gastric acid secretionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
stomach developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
renal absorptionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
renal sodium ion absorptionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cellular response to cAMPPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cellular response to epinephrine stimulusPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
adrenergic receptor signaling pathwayPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cardiac muscle cell contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
atrial cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cochlea developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during atrial cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
non-motile cilium assemblyPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
sensory perception of soundVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transporter activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
skeletal system developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
extraocular skeletal muscle developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
striated muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
endoplasmic reticulum organizationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
myoblast fusionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle adaptationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle fiber developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
release of sequestered calcium ion into cytosolVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cellular response to caffeineVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (68)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
potassium channel regulator activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
telethonin bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
protein-containing complex bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
transmembrane transporter bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
calmodulin bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein phosphatase 1 bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
outward rectifier potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein kinase A catalytic subunit bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein kinase A regulatory subunit bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
transmembrane transporter bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
ankyrin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
small molecule bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
molecular function activator activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (51)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
photoreceptor outer segmentVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
lysosomePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
apical plasma membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
Z discPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane raftPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
early endosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
endoplasmic reticulumPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cytoplasmPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
lysosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
early endosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
late endosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
endoplasmic reticulumPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
basolateral plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
apical plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
transport vesiclePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cytoplasmic vesicle membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
neuron projectionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
neuronal cell bodyPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane raftPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
ciliary basePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
lumenal side of membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
basolateral part of cellPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
monoatomic ion channel complexPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
sarcoplasmic reticulumVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
I bandVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (161)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID525225Toxicity in HBeAg-positive chronic hepatitis B patient assessed as gingival bleeding at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID434032Renal clearance in human with normal renal function at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID517934Antiviral activity against HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID434024Initial decline half life in patient with moderate renal impairment at 400 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID517939Antiviral activity against HIV1 subtype BF isolate 5 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID433847AUC (0 to t) in patient with mild renal impairment at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID525237Toxicity in HBeAg-positive chronic hepatitis B patient assessed as nausea at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID434045Mean cumulative urine excretion level in patient with moderate renal impairment at 400 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434049Metabolic stability in human HepG2 cells assessed as Telbivudine triphosphate half life2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID517935Antiviral activity against HIV1 subtype A isolate 1 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID434043Mean cumulative urine excretion level in human with normal renal function at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID517933Cytotoxicity against human HEK293 cells at 600 uM2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID525043Antiviral activity against Hepatitis B virus in HBeAg-positive chronic hepatitis B patient assessed as HBV DNA level in serum at 0.5 mg/day after 12 weeks (Rvb = 9.72 log10copies/ml)2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID525233Toxicity in HBeAg-positive chronic hepatitis B patient assessed as thrombocytopenia at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID434005AUC (0 to infinity) in patient with mild renal impairment at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434004AUC (0 to infinity) in human with normal renal function at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID1207329Inhibition of fast sodium current (INa) in Chinese Hamster Ovary (CHO) K1 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID434018Elimination half life in patient with moderate renal impairment at 400 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434037Plasma clearance in human with normal renal function at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID517946Cmax in human at 600 mg2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID517941Antiviral activity against HIV1 subtype C isolate 7 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID525219Toxicity in HBeAg-positive chronic hepatitis B patient assessed as increase in AST level at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID525231Toxicity in HBeAg-positive chronic hepatitis B patient assessed as neutropenia at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID434053Cmax for Telbivudine triphosphate in HepG2 cells after 10 uM Telbivudine treatment2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID525054Toxicity in HBeAg-positive chronic hepatitis B patient assessed as upper respiratory tract infection at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1207449Inhibition of transient outward potassium current (Ito) current in Chinese Hamster Ovary (CHO) K1 cells expressing human Kv4.3 measured using IonWorks Quattro automated patch clamp platform
AID434031Absorption half life in patient with end-stage renal disease at 200 mg, po administered as two single doses within 2 hrs of after completion of dialysis separated by 1 week washout period2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434019Elimination half life in patient with severe renal impairment at 200 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID525221Toxicity in HBeAg-positive chronic hepatitis B patient assessed as conjunctival hypermia at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID525229Toxicity in HBeAg-positive chronic hepatitis B patient assessed as myalgia at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID517942Antiviral activity against HIV1 subtype D isolate 8 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID433848AUC (0 to t) in patient with moderate renal impairment at 400 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434051Antiviral activity against HBV in HBeAg-positive patient with chronic viral infection assessed as log reduction of serum viral DNA copies/ml at 60 mg/day after 6 to 12 weeks2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434014Tmax in patient with end-stage renal disease at 200 mg, po administered as two single doses 2 hrs before dialysis separated by 1 week washout period2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID517937Antiviral activity against HIV1 subtype B isolate 3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID434020Elimination half life in patient with end-stage renal disease at 200 mg, po administered as two single doses 2 hrs before dialysis separated by 1 week washout period2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434003AUC (0 to t) in patient with end-stage renal disease at 200 mg, po administered as two single doses within 2 hrs of after completion of dialysis separated by 1 week washout period2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID525255Toxicity in HBeAg-positive chronic hepatitis B patient assessed as vomiting at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID434023Initial decline half life in patient with mild renal impairment at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID1364068Antiviral activity against telbivudine-resistant wild type hepatitis B virus infected in human Huh7 cells assessed as reduction in secreted DNA levels measured on day 7 by real-time PCR analysis2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID434012Tmax in patient with moderate renal impairment at 400 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID1207389Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells expressing hKvLQT1/hminK measured using IonWorks Quattro automated patch clamp platform
AID434011Tmax in patient with mild renal impairment at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434042Plasma clearance in patient with end-stage renal disease at 200 mg, po administered as two single doses within 2 hrs of after completion of dialysis separated by 1 week washout period2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID433841Cmax in patient with mild renal impairment at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434021Elimination half life in patient with end-stage renal disease at 200 mg, po administered as two single doses within 2 hrs of after completion of dialysis separated by 1 week washout period2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID434039Plasma clearance in patient with moderate renal impairment at 400 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434033Renal clearance in patient with mild renal impairment at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID525227Toxicity in HBeAg-positive chronic hepatitis B patient assessed as hyperphosphatemia at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID434036Renal clearance in patient with end-stage renal disease at 200 mg, po administered as two single doses 2 hrs before dialysis separated by 1 week washout period2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID433849AUC (0 to t) in patient with severe renal impairment at 200 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID525052Toxicity in HBeAg-positive chronic hepatitis B patient assessed as increase in ALT level at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID434038Plasma clearance in patient with mild renal impairment at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID1363976Antiviral activity against telbivudine-resistant hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human Huh7 cells assessed as reduction in intracellular DNA levels measured on day 7 by real-time PCR analysis2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID517940Antiviral activity against HIV1 subtype C isolate 6 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID434027Absorption half life in human with normal renal function at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID525046Antiviral activity against Hepatitis B virus in HBeAg-positive chronic hepatitis B patient assessed as mean viral clearance rate at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID433846AUC (0 to t) in human with normal renal function at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID525239Toxicity in HBeAg-positive chronic hepatitis B patient assessed as facial edema at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID525050Antiviral activity against Hepatitis B virus in HBeAg-positive chronic hepatitis B patient assessed as mean efficiency factor of blocking virus production at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID525213Toxicity in HBeAg-positive chronic hepatitis B patient assessed as chest discomfort at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID434013Tmax in patient with severe renal impairment at 200 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434008AUC (0 to infinity) in patient with end-stage renal disease at 200 mg, po administered as two single doses 2 hrs before dialysis separated by 1 week washout period2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434050Plasma clearance in human with normal renal function2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434035Renal clearance in patient with severe renal impairment at 200 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID525247Toxicity in HBeAg-positive chronic hepatitis B patient assessed as myringitis at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID525253Toxicity in HBeAg-positive chronic hepatitis B patient assessed as vaginal hemorrhage at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID434030Absorption half life in patient with severe renal impairment at 200 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID1363962Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID434022Initial decline half life in human with normal renal function at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID525048Antiviral activity against Hepatitis B virus in HBeAg-positive chronic hepatitis B patient assessed as mean rate of infected cell loss at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID525217Toxicity in HBeAg-positive chronic hepatitis B patient assessed as upper abdominal pain at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID433843Cmax in patient with severe renal impairment at 200 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID1207775Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits2013Scientific reports, , Volume: 3MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID517944Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C/G190A mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID525259Toxicity in HBeAg-positive chronic hepatitis B patient assessed as muscular weakness at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1207543Inhibition of rapid delayed inward rectifying potassium current (IKr) measured using manual patch clamp assay
AID517943Antiviral activity against HIV1 expressing reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID525241Toxicity in HBeAg-positive chronic hepatitis B patient assessed as headache at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID525243Toxicity in HBeAg-positive chronic hepatitis B patient assessed as hordeolum at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID369218Antiviral activity against woodchuck hepatitis virus infected woodchucks assessed as log reduction of serum viral DNA per ml of serum after 4 weeks2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection.
AID434048Dialytic clearance in patient with end-stage renal disease at 200 mg, po administered as single dose 2 hrs before dialysis2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434028Absorption half life in patient with mild renal impairment at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434015Tmax in patient with end-stage renal disease at 200 mg, po administered as two single doses within 2 hrs of after completion of dialysis separated by 1 week washout period2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434016Elimination half life in human with normal renal function at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID1363975Antiviral activity against telbivudine-resistant hepatitis B virus harboring reverse transcriptase M204I mutant infected in human Huh7 cells assessed as reduction in intracellular DNA levels measured on day 7 by real-time PCR analysis2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID434010Tmax in human with normal renal function at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434040Plasma clearance in patient with severe renal impairment at 200 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434041Plasma clearance in patient with end-stage renal disease at 200 mg, po administered as two single doses 2 hrs before dialysis separated by 1 week washout period2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434055Antiviral activity against HBV in HBeAg-positive patient with chronic viral infection assessed as log reduction of serum viral DNA copies/ml at 60 mg/day after 4 weeks2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434034Renal clearance in patient with moderate renal impairment at 400 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID1363957Inhibition of hepatitis B virus capsid assembly infected in human HepG2.215 cells assessed as reduction in viral DNA replication measured on day 7 by real time PCR analysis2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID434046Mean cumulative urine excretion level in patient with severe renal impairment at 200 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434052Cmax in human with normal renal function at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1363978Antiviral activity against telbivudine-resistant hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human Huh7 cells assessed as reduction in secreted DNA levels measured on day 7 by real-time PCR analysis2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID433842Cmax in patient with moderate renal impairment at 400 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434054Terminal half life in healthy human at 200 to 800 mg/day administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID525235Toxicity in HBeAg-positive chronic hepatitis B patient assessed as increase in blood CK level at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID434044Mean cumulative urine excretion level in patient with mild renal impairment at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID1363977Antiviral activity against telbivudine-resistant hepatitis B virus harboring reverse transcriptase M204I mutant infected in human Huh7 cells assessed as reduction in secreted DNA levels measured on day 7 by real-time PCR analysis2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID434002AUC (0 to t) in patient with end-stage renal disease at 200 mg, po disease as two single doses 2 hrs before dialysis separated by 1 week washout period2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID517936Antiviral activity against HIV1 subtype A isolate 2 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID517945Cytotoxicity against human HEK293 cells at 2000 uM2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID434006AUC (0 to infinity) in patient with moderate renal impairment at 400 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID1207269Inhibition of long-lasting type calcium current (hICa) in Chinese Hamster Ovary (CHO) cells expressing hCav1.2 measured using IonWorks Quattro automated patch clamp platform
AID434026Initial decline half life in patient with end-stage renal disease at 200 mg, po administered as two single doses within 2 hrs of after completion of dialysis separated by 1 week washout period2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID525249Toxicity in HBeAg-positive chronic hepatitis B patient assessed as nasophayngitis at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1207483Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) K1 cells stably expressing hERG measured using IonWorks Quattro automated patch clamp platform
AID434007AUC (0 to infinity) in patient with severe renal impairment at 200 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434025Initial decline half life in patient with severe renal impairment at 200 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID433844Cmax in patient with end-stage renal disease at 200 mg, po administered as two single doses 2 hrs before dialysis separated by 1 week washout period2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434009AUC (0 to infinity) in patient with end-stage renal disease at 200 mg, po administered as two single doses within 2 hrs of after completion of dialysis separated by 1 week washout period2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID433845Cmax in patient with end-stage renal disease at 200 mg, po administered as two single doses within 2 hrs of after completion of dialysis separated by 1 week washout period2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID434047Oral bioavailability in human with normal renal function2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID525044Hepatotoxicity in HBeAg-positive chronic hepatitis B patient assessed as reduction in alanine aminotransferase level at 600 mg/day after 12 weeks (Rvb = 163.1 IU/liter)2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID434017Elimination half life in patient with mild renal impairment at 600 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID525223Toxicity in HBeAg-positive chronic hepatitis B patient assessed as dyspnea at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID525257Toxicity in HBeAg-positive chronic hepatitis B patient assessed as peripheral neuropathy at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID434029Absorption half life in patient with moderate renal impairment at 400 mg, po administered as single dose2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
AID525245Toxicity in HBeAg-positive chronic hepatitis B patient assessed as insomnia at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID517938Antiviral activity against HIV1 subtype B isolate 4 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID525251Toxicity in HBeAg-positive chronic hepatitis B patient assessed as proteinuria at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID525215Toxicity in HBeAg-positive chronic hepatitis B patient assessed as abdominal discomfort at 600 mg/day2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (461)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's96 (20.82)29.6817
2010's328 (71.15)24.3611
2020's37 (8.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.13 (24.57)
Research Supply Index6.35 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index72.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials85 (17.49%)5.53%
Reviews106 (21.81%)6.00%
Case Studies31 (6.38%)4.05%
Observational17 (3.50%)0.25%
Other247 (50.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (67)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Observation Of Safety And Survival Of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Combined With Anti-hepatitis B Virus Therapy [NCT01102335]Phase 480 participants (Anticipated)Interventional2010-04-30Recruiting
Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET [NCT01065818]6 participants (Actual)Interventional2009-08-31Terminated(stopped due to Lack of funding)
FLT-PET as an Imaging Biomarker in Patients Receiving the Combination of Cell Cycle Inhibitors Temsirolimus, Topotecan, and Bortezomib [NCT01143779]Phase 13 participants (Actual)Interventional2010-06-30Completed
[NCT01337791]Phase 488 participants (Actual)Interventional2008-08-31Completed
Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B [NCT01380951]Phase 4120 participants (Anticipated)Interventional2011-05-31Recruiting
The Effect of Telbivudine on Renal Function and Proteinuria in Patients With Chronic Hepatitis B Infection and Chronic Kidney Diseases [NCT02049736]0 participants (Actual)Interventional2013-12-31Withdrawn(stopped due to unable to recruit patients)
An Exploratory, Randomized, Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug Alone in HBeAg Negative Chronic Hepatitis B Patients [NCT01260610]0 participants (Actual)Interventional2011-06-30Withdrawn(stopped due to lack of funds)
An Open Label Trial of Telbivudine (LdT) in Adults With Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies [NCT00142298]Phase 31,869 participants (Actual)Interventional2005-03-31Completed
An Open-label, Multicenter, Randomized Study of Combination Therapy With Oral LDT600 (Telbivudine) Plus Adefovir Dipivoxil Versus Adefovir Dipivoxil Alone in HBeAg-positive Patients With Chronic Hepatitis B Who Are Lamivudine Resistant [NCT00376259]Phase 343 participants (Actual)Interventional2007-01-31Terminated(stopped due to The study was not completed as planned and was terminated early with agreement from the European Medicines Agency (EMEA))
OPTIMA: A Randomized, Open-label, 156-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept [NCT01379508]Phase 4241 participants (Actual)Interventional2011-03-21Completed
The Effect of Anti-viral Drugs Used in Late Pregnancy in Mothers With Hepatitis B Virus Infection on Long-term Development of Children [NCT02301650]400 participants (Anticipated)Observational2014-10-31Enrolling by invitation
The Effect of Telbivudine on Renal Function in Chronic Hepatitis B Patients With Mild to Moderate Renal Impairment [NCT03778567]Phase 431 participants (Actual)Interventional2013-08-01Completed
A Single Arm, Multicenter, Open-label, 52-week, the Omnibus Extension Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B and Are HBV DNA PCR Negative at the End [NCT00646503]Phase 4150 participants (Actual)Interventional2008-03-31Completed
An Open-label, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B [NCT00781105]Phase 42,200 participants (Actual)Interventional2008-08-01Completed
Case-control Study of Antiviral Therapy During Entire and the Third Trimester of Pregnancy in Preventing MTCT of HBV in Mothers With High Serum HBV DNA Load [NCT02253485]600 participants (Anticipated)Observational2012-08-31Enrolling by invitation
A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection [NCT00939068]Phase 4180 participants (Anticipated)Interventional2008-02-29Enrolling by invitation
A Randomized, Prospective, Multicenter, Open-label Study to Evaluate the Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir in HBeAg-positive Chronic Hepatitis B Patients [NCT01588912]Phase 4104 participants (Anticipated)Interventional2012-04-30Recruiting
A Randomized, Open-label, Controlled, Multi-center Two-year Study Comparing Efficacy and Safety of Telbivudine, 600 mg PO in Combination With Peginterferon Alpha-2a sq 180 µg With Peginterferon Alpha-2a Monotherapy, and With Telbivudine Monotherapy in Tre [NCT00412750]Phase 3159 participants (Actual)Interventional2006-12-31Terminated(stopped due to Enrollment stopped for safety issues)
Randomized, Double-Blind Trial of Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis [NCT00076336]Phase 3232 participants (Actual)Interventional2003-12-31Completed
A Two-year, Randomized, Controlled, Open-label, Virologic Response Adaptive Design, Multicenter Study to Optimize Antiviral Efficacy of Telbivudine in Adult Patients With HBeAg Positive Chronic Hepatitis B (EFFORT Study) [NCT00962533]Phase 4606 participants (Actual)Interventional2009-08-31Completed
Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine [NCT02774837]Phase 4146 participants (Actual)Interventional2016-04-30Active, not recruiting
A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in Chronic Hepatitis B [NCT02615639]Phase 1/Phase 2450 participants (Anticipated)Interventional2015-11-30Not yet recruiting
A Randomized, Open-label, Controlled, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine 600 mg and Tenofovir Disproxil Fumarate 300 mg in Combination or Telbivudine 600 mg or Tenofovir Disproxil Fumarate 300 mg Mono [NCT00804622]Phase 215 participants (Actual)Interventional2008-12-31Completed
Randomized, Open-Label, Phase IV Trial in Nucleus(t)id-Naive Patients With Chronic Hepatitis B to Examine the Effect of Telbivudine Compared to Lamivudine on the Early Dynamics and Kinetics of Viral Suppression (Early-Viral-Dynamics Study) [NCT00710216]Phase 440 participants (Anticipated)InterventionalWithdrawn(stopped due to Sponsor withdraw)
Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study) [NCT02826070]Phase 4130 participants (Actual)Interventional2015-04-30Active, not recruiting
A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Telbivudine (LDT600) in Children and Adolescents With Chronic Hepatitis B [NCT00907894]Phase 122 participants (Actual)Interventional2009-02-28Completed
A 26 Week Randomized, Open Label, Multi-center Study of the Efficacy and Safety of Telbivudine 600 mg Once Daily Versus Adefovir Dipivoxil 10mg Once Daily in Subjects With Compensated Chronic Hepatitis B and Sub-optimal Response to at Least 48 Weeks of Ad [NCT00606099]Phase 40 participants (Actual)Interventional2007-11-30Withdrawn(stopped due to study was cancelled)
A Single-arm, Multicenter, Open-label, 52-week Treatment, Extension Study to CLDT600ACN04 Study to Evaluate the Efficacy (Including Histological Improvement) and Safety in Fourth to Sixth Year of Telbivudine Treatment in Patients With Chronic Hepatitis B [NCT00877149]Phase 480 participants (Anticipated)Interventional2009-03-31Completed
Study the Effect of Nucleoside on Host Immune in Patients With CHB [NCT01480492]56 participants (Actual)Interventional2010-01-31Completed
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma [NCT01410630]66 participants (Actual)Observational2017-09-07Completed
An Open-label, Single-arm, Multicenter, Study of Telbivudine in Nucleos(t)Ide-naïve Subjects of Black/African American or Hispanic/Latino Origin With Compensated Chronic Hepatitis B Virus (HBV) Infection [NCT00862706]Phase 40 participants (Actual)Interventional2009-04-30Withdrawn(stopped due to Stopped with Patients)
Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection. [NCT00810524]Phase 4600 participants (Anticipated)Interventional2007-01-31Recruiting
A Single-Center, Open-Label Study to Evaluate the Renal Function Improvement in Lamivudine Long Term Used HBsAg Positive Kidney Transplantation Patients After Switch to Telbivudine Treatment. [NCT02894554]Phase 419 participants (Actual)Interventional2014-07-31Terminated(stopped due to clinical myalgia)
A Randomized Open Label Study Evaluating the Efficacy of Continuous Telbivudine Versus Lamivudine in Patients With HBeAg-negative Chronic Hepatitis B Who Had Previously Achieved an Undetectable Viral Load During 24 Weeks of Telbivudine Therapy [NCT01005238]Phase 427 participants (Actual)Interventional2009-09-30Terminated(stopped due to unsufficient patient recruitment)
Prospective Exploratory Study to Describe in CHB naïve and Non-naïve Patients, Hepatitis B Virus (HBV) Kinetics During the First 24 Weeks of Treatment With Telbivudine [NCT00640588]Phase 330 participants (Actual)Interventional2008-03-31Completed
A Randomized, Open-label, Controlled, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine 600 mg and Tenofovir Disproxil Fumarate 300 mg in Combination or Telbivudine 600 mg or Tenofovir Disproxil Fumarate 300 mg Mono [NCT00805675]Phase 383 participants (Actual)Interventional2008-11-30Completed
A Prospective, Randomized, Trial to Investigate the Effect of Continued Adefovir Versus Combination Regimens of Telbivudine Plus Adefovir, and Telbivudine Plus Tenofovir in Patients With Chronic Hepatitis B and Suboptimal Viral Suppression (PROACTIV Study [NCT00409019]Phase 40 participants (Actual)InterventionalWithdrawn(stopped due to Study cancelled: Withdrawn before enrollment of any participants)
A Phase IIb Extension Study of LdT (Telbivudine), Lamivudine or LdT Plus Lamivudine in Patients With Chronic Hepatitis B Who Have Completed Study NV-02B-003 [NCT00124241]Phase 20 participants InterventionalCompleted
An Open Label, Response Adaptive Study of Telbivudine in Adults With HBeAg Positive Compensated CHB [NCT00537537]Phase 4100 participants (Actual)Interventional2007-08-31Completed
PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer [NCT00236275]Phase 360 participants (Actual)Interventional2004-05-31Completed
A Phase III Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B [NCT00131742]Phase 30 participants Interventional2004-07-31Completed
A Randomized, Open-Label Trial of Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B [NCT00115245]Phase 30 participants Interventional2004-11-30Completed
The Role of 3-Deoxy-3[18]Fluorothymidine Positron Emission Tomography (FLT-PET) in Proliferation of Colorectal Liver Metastases [NCT00145665]Phase 1/Phase 280 participants (Anticipated)Interventional2005-01-31Terminated(stopped due to no accrual achieved)
An Extension to A Randomized, Open-label, Controlled, Multicenter, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine (LDT600) 600 mg or Entecavir (ETV) 0.5 mg Given Over 12 Weeks on the Kinetics of Hepatitis B Virus [NCT00467545]Phase 444 participants (Actual)Interventional2007-04-30Completed
A Two-year, Open-label, Virological Response Adaptive Design, Multicenter Study to Evaluate Efficacy of Telbivudine in HBeAg Negative Adult CHB Patients With Roadmap Strategy [NCT01521975]Phase 4360 participants (Actual)Interventional2011-01-01Completed
A 3-year, Open-label, Multi-center Extension Trial of Telbivudine Therapy for Patients Previously Treated in EFFORT Clinical Trial [NCT01529255]Phase 4576 participants (Anticipated)Interventional2011-08-31Active, not recruiting
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B [NCT00057265]Phase 30 participants Interventional2003-02-28Completed
A Randomized, Double-Blind Trial of Telbivudine (LdT) Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis. [NCT00275652]Phase 36 participants Interventional2004-06-30Completed
A Randomized, Blinded, Phase IIb Trial of Telbivudine (LdT) Versus the Combination of Telbivudine and Valtorcitabine (Val-LdC) in Patients With Chronic Hepatitis B [NCT00128544]Phase 2130 participants Interventional2005-05-31Completed
Multicenter, Pilot Study of Telbivudine (LdT) Anti-HBV Treatment Prior to the Initiation of Highly Active Antiretroviral Therapy Containing Lamivudine in Subjects Coinfected With HBV and HIV [NCT00051090]0 participants (Actual)InterventionalWithdrawn
A Randomized Trial of Switching Antiviral Therapy From Lamivudine to Telbivudine (LdT) vs. Continued Lamivudine Treatment in Adults With Chronic Hepatitis B [NCT00132652]Phase 3240 participants Interventional2005-02-28Completed
A Randomized, Open-label, Controlled, Multicenter, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine (LDT600) 600 mg or Entecavir (ETV) 0.5 mg Given Over 12 Weeks on the Kinetics of Hepatitis B Virus (HBV) DNA in Ad [NCT00412529]Phase 344 participants (Actual)Interventional2006-12-31Completed
Antiviral Efficacy of Continuing Lamivudine Plus Adefovir or Switching to Telbivudine Plus Adefovir in HBeAg-positive Lamivudine-refractory Chronic Hepatitis B Patients Who Have Suboptimal Response to Lamivudine Plus Adefovir for at Least 12 Months [NCT01270165]Phase 3110 participants (Anticipated)Interventional2010-06-30Recruiting
Telbivudine in the Third Trimester of Pregnancy to Prevent Mother-to-infant Transmission of HBV [NCT01637844]Phase 4335 participants (Actual)Interventional2012-04-30Completed
[NCT01693679]Phase 4120 participants (Anticipated)Interventional2012-09-30Active, not recruiting
A Prospective Randomized Controlled Study to Compare the Efficacy of Combined Tenofovir Plus Telbuvidine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B. [NCT01732224]69 participants (Actual)Interventional2012-11-30Completed
The Efficacy and Safety of Telbivudine and Lamivudine Use in Highly Viremic Mothers to Prevent Hepatitis B Transmission [NCT01743079]Phase 4700 participants (Actual)Interventional2009-01-31Completed
Nucleoside Analogue in Late Preganancy to Prevent Vertical Transmission of Hepatitis B Virus [NCT01788371]Phase 4700 participants (Actual)Interventional2009-03-31Completed
Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study [NCT01804387]Phase 460 participants (Anticipated)Interventional2011-05-31Recruiting
A Randomized, Open-label Trial Comparing Telbivudine vs, Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Who Have Achieved Serum HBV DNA Undetectability by Preceding Entecavir Treatment [NCT01595685]Phase 398 participants (Actual)Interventional2012-05-31Completed
A Randomized, Multicenter, Prospective Study to Compare Antiviral Efficacy and Safety of Switching to ETV Plus TDF Versus Maintaining LAM/LDT Plus ADF Combination in CHC With PVR to LAM/LDF Plus ADF Combination Rescue Therapy for YMDD Mutation [NCT01597934]Phase 4104 participants (Anticipated)Interventional2012-08-31Active, not recruiting
A Randomized, Double-blind, 104-weeks Treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Telbivudine Oral Solution and Tablets in Children and Adolescents With Compensated HBeAg-positive and Negative Chronic Hepatitis B [NCT02058108]Phase 353 participants (Actual)Interventional2014-10-31Terminated(stopped due to Study terminated on the recommendation of an independent Data Monitoring Committee (DMC) subsequent to an interim efficacy analysis for futility.])
Combination Therapy of Tenofovir and Telbivudine in Immune-tolerant Patients With Chronic Hepatitis B Awaiting Assisted Reproduction [NCT02338674]Phase 1/Phase 2121 participants (Actual)Interventional2014-10-31Completed
Replacement of Lamivudine by Telbivudine to Improve Renal Function for Post-transplant Hepatitis B Patients - a Randomized Clinical Trial [NCT02447705]Phase 2/Phase 3120 participants (Actual)Interventional2013-06-30Completed
A Prospective, Observational, Single-center Post-marketing Surveillance Study of Telbivudine in Chronic Hepatitis B Adults With HBeAg Positive/Negative. [NCT00970216]160 participants (Actual)Observational2009-02-28Completed
Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial [NCT01799486]Phase 4300 participants (Anticipated)Interventional2013-02-28Active, not recruiting
The Safety of Anti-viral Therapy in Preventing Mother-to-child Transmission of Hepatitis B Virus in Pregnant Women After Discontinuation [NCT03468907]Phase 4111 participants (Actual)Interventional2015-06-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00076336 (5) [back to overview]Number of Participants With Clinical Response
NCT00076336 (5) [back to overview]Number of Participants With Improvement, Stabilization, and Worsening in a Modified (3-component) CTP Score
NCT00076336 (5) [back to overview]Number of Participants With Improvement, Stabilization, and Worsening in Child-Turcotte-Pugh (CTP) Score at Week 52 and Week 104
NCT00076336 (5) [back to overview]Duration of Initial Clinical Response
NCT00076336 (5) [back to overview]Time to Initial Clinical Response
NCT00142298 (6) [back to overview]Percentage of Participants Who Maintained Therapeutic Response [Group A: Feeder Studies 2401/2402/010]
NCT00142298 (6) [back to overview]Percentage of Participants Who Maintained Therapeutic Response [Group A: LAM Pool 2302/015]
NCT00142298 (6) [back to overview]Percentage of Participants Who Maintained Therapeutic Response [Group A: LdT Pool 2302/015]
NCT00142298 (6) [back to overview]Percentage of Participants With Maintained Clinical Response [Group B: LAM 2301]
NCT00142298 (6) [back to overview]Percentage of Participants With Maintained Clinical Response [Group B: LdT 2301]
NCT00142298 (6) [back to overview]Percentage of Participants With Sustained Therapeutic Response [Group C: LdT Pool and LAM Pool (2302/015)]
NCT00376259 (2) [back to overview]Change From Baseline in Mean Hepatitis B Virus (HBV) DNA Concentration
NCT00376259 (2) [back to overview]Percentage of Participants Achieving Specified Clinical and Laboratory Safety Criteria
NCT00412529 (8) [back to overview]The Area Under the Curve (AUC) of HBV DNA Change.
NCT00412529 (8) [back to overview]Change in Alanine Aminotransferase (ALT) Levels
NCT00412529 (8) [back to overview]Change in Mean HBV DNA Level
NCT00412529 (8) [back to overview]Change in Mean Hepatitis B Virus (HBV) DNA Levels
NCT00412529 (8) [back to overview]Number of Patients Who Are Polymerase Chain Reaction (PCR) Negative
NCT00412529 (8) [back to overview]Characterization of Very Early Viral Kinetics: Estimation of Viral Clearance
NCT00412529 (8) [back to overview]Characterization of Very Early Viral Kinetics: Estimation of the Efficiency Factor of Blocking Virus Production
NCT00412529 (8) [back to overview]Characterization of Very Early Viral Kinetics: Estimation of the Rate of Infected Cell Loss
NCT00412750 (4) [back to overview]Change From Baseline in HBV DNA Concentration
NCT00412750 (4) [back to overview]Percentage of Participants Who Experienced Virologic Breakthrough at Weeks 48 and 52
NCT00412750 (4) [back to overview]Percentage of Participants With HBV DNA Non-detectability and Alanine Aminotransferase (ALT) Normalization at Week 12 and Week 24 in Participants With HBeAg-positive Chronic Hepatitis B (CHB)
NCT00412750 (4) [back to overview]Percentage of Participants With Hepatitis B 'e' Antigen (HBeAg) Loss and HBeAg Seroconversion
NCT00805675 (9) [back to overview]"Percentage of Patients Who Achieve Hepatitis B e Antigen (HBeAg) Loss and HBeAg Seroconversion at Week 12"
NCT00805675 (9) [back to overview]Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Week 12.
NCT00805675 (9) [back to overview]Characterization of Very Early Viral Kinetics Through Efficiency Factor of Blocking Virus Production.
NCT00805675 (9) [back to overview]Characterization of Very Early Viral Kinetics Through Estimated Viral Load
NCT00805675 (9) [back to overview]Characterization of Very Early Viral Kinetics Through Half-live of Free Virus
NCT00805675 (9) [back to overview]Characterization of Very Early Viral Kinetics Through Viral Clearance
NCT00805675 (9) [back to overview]Percentage of Patients Who Are Polymerase Chain Reaction(PCR)Negative at Week 12
NCT00805675 (9) [back to overview]Characterization of Very Early Viral Kinetics Through Rate of Infected Cell Loss
NCT00805675 (9) [back to overview]Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Weeks 2, 4 and 8.
NCT00970216 (1) [back to overview]HBV-DNA < 300 Copies/mL in 48 Weeks
NCT01379508 (4) [back to overview]eGFR Change From Baseline in Telbivudine Arm vs Tenofovir Arm Over the Course of the Study
NCT01379508 (4) [back to overview]Percentage of Participants Achieving HBV DNA < 300 Copies/mL (51 IU/mL) at Week 52 (rITT Population) -
NCT01379508 (4) [back to overview]Percentage of Participants Achieving Secondary Efficacy Endpoints at Week 156 (mITT)
NCT01379508 (4) [back to overview]Percentage of Patients Achieving Secondary Efficacy Endpoints (rITT)
NCT02058108 (14) [back to overview]Number of Patients Achieving Serum HBV DNA Level of <300 Copies/mL (51 IU/mL) at Week 24
NCT02058108 (14) [back to overview]Number of Participants With On-Treatments Adverse Events, Serious Adverse Events, and Death
NCT02058108 (14) [back to overview]Number of Patients Achieving a Composite Endpoints (HBV DNA < 300 Copies/mL (51 IU/mL), ALT Normalization and HBeAg Seroconversion) at Week 52 and 104
NCT02058108 (14) [back to overview]Number of Patients Achieving a Composite Endpoints (HBV DNA < 300 Copies/mL (51 IU/mL), ALT Normalization and HBeAg Seroconversion) at Week 52 and 104
NCT02058108 (14) [back to overview]Number of Patients Achieving Cumulative Rate of Virological Breakthrough (VB) at Week 52 and 104
NCT02058108 (14) [back to overview]Number of Patients Achieving HBV DNA< 300 Copies/mL (51 IU/mL) at Week 52 and Week 104
NCT02058108 (14) [back to overview]Number of Patients Achieving HBV DNA< 300 Copies/mL (51 IU/mL) at Week 52 and Week 104
NCT02058108 (14) [back to overview]Number of Participants With Treatment Emergent Genotypic Resistance Associated With VB, or in Patients With HBV DNA≥300 Copies/mL (51 IU/mL) at Week 24 and Discontinued From the Study
NCT02058108 (14) [back to overview]Number of Patients Whose Baseline ALTs Were Abnormal and Subsequently Normalized at Week 24, 52 and 104
NCT02058108 (14) [back to overview]Number of Patients With HBeAg Loss, HBeAg Seroconversion at Week 24, 52 and 104
NCT02058108 (14) [back to overview]Number of Patients With HBeAg Loss, HBeAg Seroconversion at Week 24, 52 and 104
NCT02058108 (14) [back to overview]Number of Patients With HBsAg Loss, HBsAg Seroconversion at Week 24, 52 and 104
NCT02058108 (14) [back to overview]Number of Patients With HBsAg Loss, HBsAg Seroconversion at Week 24, 52 and 104
NCT02058108 (14) [back to overview]Number of Patients Whose Baseline ALTs Were Abnormal and Subsequently Normalized at Week 24, 52 and 104

Number of Participants With Clinical Response

Clinical response defined as achieving all of the following 3 criteria on at least 2 consecutive visits or at the last on-treatment visit: Serum hepatitis B virus (HBV) DNA < 4 log10 copies/mL, normal Alanine transaminase (ALT) level (ALT ≤ Upper Limit of Normal (ULN)), and improvement (a 2- point or greater reduction in Child-Turcotte-Pugh (CTP) score) or stabilization (not more than a 1-point change in CTP score), compared to the baseline value. CTP scores range from 5-15, higher scores indicate more liver impairment. For Improvement/Stabilization, either of the individual criteria were met. (NCT00076336)
Timeframe: From Baseline to Week 52

,
InterventionParticipants (Number)
Clinical ResponseHBV DNA < 4log10copies/mLNormal ALTImprovement/stabilization in CTPImprovement in CTP (reduction ≥ 2)Stabilization in CTP (absolute change ≤ 1)
Lamivudine 100 mg628281964348
Telbivudine 600 mg658578963456

[back to top]

Number of Participants With Improvement, Stabilization, and Worsening in a Modified (3-component) CTP Score

Modified CTP was calculated using the 3 biochemical-components (serum bilirubin, albumin, and prothrombin). Total scores range from 3-9; higher scores indicate more liver impairment. Improvement was defined as 2-point or greater reduction in score from baseline. Stabilization comprises a score change of 1-point or less from baseline. Worsening of CTP score was defined as a 2-point or greater increase from baseline. The rationale for assessing changes in this modified (3-component) CTP score is that this maneuver removed the two subjective components of CTP scoring (ascites and encephalopathy). (NCT00076336)
Timeframe: Baseline and Week 104

,
InterventionParticipants (Number)
Improvement at Week 104Stabilization at Week 104Worsening at Week 104
Lamivudine 100 mg315429
Telbivudine 600 mg305727

[back to top]

Number of Participants With Improvement, Stabilization, and Worsening in Child-Turcotte-Pugh (CTP) Score at Week 52 and Week 104

"Child-Turcotte-Pugh (CTP) uses 2 clinical variables, ascites and encephalopathy, and 3 laboratory parameters, serum bilirubin, albumin, and prothrombin time. Each variable is assigned a score from 1 to 3, with the combined score comprising the CTP score range of 5 to 15 points. Higher scores indicate more impaired liver function. Worsening of CTP score was defined as a 2-point or greater increase from baseline, improvement in CTP score was defined as a 2-point or greater reduction from baseline, and stabilization of CTP score was defined as a change of 1-point or less from baseline." (NCT00076336)
Timeframe: From Baseline to weeks 52 and 104

,
InterventionParticipants (Number)
Improvement At Week 52Stabilization At Week 52Worsening At Week 52Improvement At Week 104Stabilization At Week 104Worsening At Week 104
Lamivudine 100 mg445218463830
Telbivudine 600 mg366018444228

[back to top]

Duration of Initial Clinical Response

Kaplan-Meier method was used. The duration was calculated as: date of last visit before initial loss of clinical response - date of initial clinical response occurred+1. If a patient did not lose clinical response, it was then censored at the efficacy overall censoring date. (NCT00076336)
Timeframe: Baseline to Week 104

InterventionDays (Mean)
Telbivudine 600 mg473.1
Lamivudine 100 mg456.3

[back to top]

Time to Initial Clinical Response

Time to Clinical Response defined as the number of days elapsed from the baseline visit to achieving initial Clinical Response. (NCT00076336)
Timeframe: From Baseline to Week 104

InterventionDays (Mean)
Telbivudine 600 mg137.5
Lamivudine 100 mg125.2

[back to top]

Percentage of Participants Who Maintained Therapeutic Response [Group A: Feeder Studies 2401/2402/010]

The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA < 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (>1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients. (NCT00142298)
Timeframe: 52 weeks, 104 weeks

,,
InterventionPercentage of Participants (Number)
HBeAg Positive: 52 week (n = 103, 79, 43)HBeAg Positive: 104 week (n = 66, 15, 30)HBeAg Negative: 52 week (n = 0, 37, 0)HBeAg Negative: 104 week (n = 0, 10, 0)
Group A: Feeder Study 01069.876.7NANA
Group A: Feeder Study 240177.781.8NANA
Group A: Feeder Study 240235.446.754.160.0

[back to top]

Percentage of Participants Who Maintained Therapeutic Response [Group A: LAM Pool 2302/015]

The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA < 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (>1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients. (NCT00142298)
Timeframe: 52 weeks, 104 weeks

InterventionPercentage of Participants (Number)
HBeAg Positive: week 52 (n=338)HBeAg Positive: week 104 (n=101)HBeAg Negative: week 52 (n=182)HBeAg Negative: week 104 (n=79)
Group A : LAM Pool 2302/01560.165.380.881.0

[back to top]

Percentage of Participants Who Maintained Therapeutic Response [Group A: LdT Pool 2302/015]

The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA < 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (>1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients. (NCT00142298)
Timeframe: 156 weeks, 208 weeks (from feeder study baseline)

InterventionPercentage of participants (Number)
HBeAg Positive: week 156 (n=338)HBeAg Positive: week 208 (n=252)HBeAg Negative: week 156 (n=197)HBeAg Negative: week 208 (n=168)
Group A : LdT Pool 2302/01567.273.881.786.3

[back to top]

Percentage of Participants With Maintained Clinical Response [Group B: LAM 2301]

Maintained clinical response is defined as achievement of serum HBV DNA < 4 log10 copies/mL, normal serum ALT level and improvement or stabilization in Child-Turcotte-Pugh (CTP) score. Total CTP score ranges from 5 to 15; higher scores indicate liver impairment. Improvement is defined as a 2-point or greater reduction in CTP score, and stabilization is defined as a less than 2-point change in CTP score, compared to the patient's baseline value. Analysis was done on the overall per protocol (PP) population and separately for the HBeAg-positive and HBeAg-negative subpopulation. (NCT00142298)
Timeframe: 52 weeks,104 weeks

InterventionPercentage of Participants (Number)
HBeAg Positive: week 52 (n=4)HBeAg Positive: week 104 (n=1)HBeAg Negative: week 52 (n=11)HBeAg Negative: week 104 (n=5)Overall: week 52 (n= 15)Overall: week 104 (n= 6)
Group B : LAM 230110010072.710080.0100

[back to top]

Percentage of Participants With Maintained Clinical Response [Group B: LdT 2301]

Maintained clinical response is defined as achievement of serum HBV DNA < 4 log10 copies/mL, normal serum ALT level and improvement or stabilization in Child-Turcotte-Pugh (CTP) score. Total CTP score ranges from 5 to 15; higher scores indicate liver impairment. Improvement is defined as a 2-point or greater reduction in CTP score, and stabilization is defined as a less than 2-point change in CTP score, compared to the patient's baseline value. Analysis was done on the overall per protocol (PP) population and separately for the HBeAg-positive and HBeAg-negative subpopulation. (NCT00142298)
Timeframe: 156 weeks, 208 weeks (from feeder study baseline)

InterventionPercentage of Participants (Number)
HBeAg Positive: week 156 (n= 4)HBeAg Positive: week 208 (n= 1)HBeAg Negative: week 156 (n= 11)HBeAg Negative: week 208 (n= 7)Overall: Week 156 (n= 15)Overall: Week 208 (n= 8)
Group B : LdT 230110010072.771.480.075.0

[back to top]

Percentage of Participants With Sustained Therapeutic Response [Group C: LdT Pool and LAM Pool (2302/015)]

The primary efficacy endpoint for Group C patients was the percentage of patients with sustained therapeutic response (defined as HBV DNA < 5 log10 copies/mL and either HBeAg loss or ALT normalized) at Weeks 52 and 104 of off-treatment follow-up. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is ALT within normal limits for a patient with an elevated ALT level (>1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients. (NCT00142298)
Timeframe: 52 weeks,104 weeks

,
InterventionPercentage of Participants (Number)
HBeAg Positive: week 52 (n= 53, 42)HBeAg Positive: week 104 (n= 42, 32)HBeAg Negative: week 52 (n= 3, 5)HBeAg Negative: week 104 (n= 3, 6)
Group C : LdT Pool 2302/01569.857.10.00.0
Group C: LAM Pool 2302/01573.862.580.083.3

[back to top]

Change From Baseline in Mean Hepatitis B Virus (HBV) DNA Concentration

Efficacy was assessed by the change from baseline in mean HBV DNA concentration after 12, 24, 48 and 60 weeks of treatment. (NCT00376259)
Timeframe: Baseline to 12 weeks, 24 weeks, 48 weeks and 60 weeks

,
InterventionLog10 Copies/mL (Mean)
At Baseline (N = 21, 20)At Week 12Change from Baseline to Week 12At Baseline (N = 20, 20)At Week 24Change from Baseline to Week 24At Baseline (N = 13, 9)At Week 48Change from Baseline to Week 48At Baseline (N = 2, 3)At Week 60Change from Baseline to Week 60
Adefovir Monotherapy10.1275.515-4.61210.1275.161-4.96610.2075.272-4.93410.0974.330-5.767
Combination Therapy10.2404.405-5.83510.2793.678-6.60110.6523.274-7.3789.6053.360-6.245

[back to top]

Percentage of Participants Achieving Specified Clinical and Laboratory Safety Criteria

Undetectable HBV DNA = HBV DNA <300 copies/ml. Serum aminotransferase (ALT) normalization is defined as ALT within normal limits on 2 successive visits for a pt. with an elevated ALT level (>=1.0 x ULN) at baseline (BL). Hepatitis B e antigen (HBeAg) loss is defined as the loss of detectable serum HBeAg in a pt. who was HBeAg +ve at BL. HBeAg seroconversion is defined as HBeAg loss with detectable HBeAb. Hepatitis B surface antigen (HBsAg) loss is defined as the loss of detectable serum HBsAg in a pt. who was HBsAg +ve at BL. HBsAg seroconversion is defined as HBsAg loss with detectable HBsAb. (NCT00376259)
Timeframe: 12 week, 24 week, 48 week and 60 weeks

,
InterventionPercentage of participants (Number)
Undetectable HBV DNA at week 12Undetectable HBV DNA at week 24Undetectable HBV DNA at week 48Undetectable HBV DNA at week 60Serum ALT normalization at week 12Serum ALT normalization at week 24Serum ALT normalization at week 48Serum ALT normalization at week 60HBeAg loss at week 12HBeAg loss at week 24HBeAg loss at week 48HBeAg loss at week 60HBeAg seroconversion at week 12HBeAg seroconversion at week 24HBeAg seroconversion at week 48HBeAg seroconversion at week 60HBsAg loss at week 12HBsAg loss at week 24HBsAg loss at week 48HBsAg loss at week 60HBsAg seroconversion at week 12HBsAg seroconversion at week 24HBsAg seroconversion at week 48HBsAg seroconversion at week 60
Adefovir Monotherapy5.010.00.00.025.035.033.30.00.05.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Combination Therapy4.815.038.50.040.055.069.250.00.05.023.10.00.00.015.40.00.00.00.00.00.00.00.00.0

[back to top]

The Area Under the Curve (AUC) of HBV DNA Change.

In AUC efficacy analyses, all the visits from baseline to Week 12 visit (including the planned and the repeated) with a non-missing HBV DNA level were included. (NCT00412529)
Timeframe: From Baseline to Week 12

Intervention(log10 copies/mL) * days (Mean)
Telbivudine-453.5
Entecavir-442.6

[back to top]

Change in Alanine Aminotransferase (ALT) Levels

(NCT00412529)
Timeframe: From Baseline to Week 12

,
InterventionIU/L (Mean)
BaselineAt Week 12Change from Baseline to Week 12
Entecavir170.254.0-116.3
Telbivudine163.155.1-108.0

[back to top]

Change in Mean HBV DNA Level

Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA.HBV DNA reductions, considered as the repeated measures, from baseline to Weeks 2, 4, 8. (NCT00412529)
Timeframe: Baseline (day 1) to Weeks 2, 4, 8

,
Interventionlog10 copies/mL (Mean)
Change from Baseline to week 2 :(N=20, 21)Change from Baseline to week 4 : (N= 23, 21)Change from Baseline to week 8 : (N= 23, 21)
Entecavir-3.974-4.875-5.976
Telbivudine-3.999-5.273-6.161

[back to top]

Change in Mean Hepatitis B Virus (HBV) DNA Levels

Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA. (NCT00412529)
Timeframe: Baseline (day 1) to Week 12 (day 85)

,
Interventionlog10 copies/mL (Mean)
Baseline (day 1)At Week 12Change from Baseline to week 12
Entecavir9.7213.194-6.527
Telbivudine10.2903.669-6.621

[back to top]

Number of Patients Who Are Polymerase Chain Reaction (PCR) Negative

PCR negative was considered <300 copies/mL. PCR positive was considered =>300 copies/mL. (NCT00412529)
Timeframe: At Week 12

,
InterventionParticipants (Number)
<300 copies/mL>= 300 copies/mL
Entecavir615
Telbivudine221

[back to top]

Characterization of Very Early Viral Kinetics: Estimation of Viral Clearance

"Viral kinetic parameters were estimated with a bi-phasic mathematical model:~V(t) = (1-ε)pI(t) - cV(t)~I(t) = (1- η)TV(t) - δI(t)~V serum viral load, I productively infected cells, ε efficiency factor of blocking virus production, p viral production rate, c viral clearance rate, η efficiency factor of blocking de novo infection, β de novo infection rate, T uninfected target cells, δ rate of infected cell loss. Maximum-likelihood estimation for the viral kinetic parameters entailed fitting a nonlinear differential equation system via the least-squares approach from serum HBV DNA data." (NCT00412529)
Timeframe: Baseline to 12 weeks

Interventionclearance per day (Mean)
Telbivudine0.809
Entecavir1.002

[back to top]

Characterization of Very Early Viral Kinetics: Estimation of the Efficiency Factor of Blocking Virus Production

Viral kinetic parameters were estimated with a bi-phasic mathematical model of HBV DNA by using compartments of free virus, infected cells, and uninfected target cells. The model parameter of interest was the effectiveness of the drug in blocking virus production from infected cells (efficacy, ε). Blocking efficiency was within the range between 0 and 1. (NCT00412529)
Timeframe: Baseline to 12 weeks

Interventionpercentage of blocking efficiency (Mean)
Telbivudine0.991
Entecavir0.992

[back to top]

Characterization of Very Early Viral Kinetics: Estimation of the Rate of Infected Cell Loss

"Viral kinetic parameters were estimated with a bi-phasic mathematical model:~V(t) = (1-ε)pI(t) - cV(t)~I(t) = (1- η)TV(t) - δI(t)~V serum viral load, I productively infected cells, ε efficiency factor of blocking virus production, p viral production rate, c viral clearance rate, η efficiency factor of blocking de novo infection, β de novo infection rate, T uninfected target cells, δ rate of infected cell loss. Maximum-likelihood estimation for the viral kinetic parameters entailed fitting a nonlinear differential equation system via the least-squares approach from serum HBV DNA data." (NCT00412529)
Timeframe: Baseline to 12 weeks

Interventioninfected cell loss per day (Mean)
Telbivudine0.075
Entecavir0.071

[back to top]

Change From Baseline in HBV DNA Concentration

The change from baseline in HBV DNA concentration at Weeks 12 and 24 was analyzed using an analysis of covariance (ANCOVA) model with baseline HBV DNA concentration (log10 copies/ml) as a covariate, treatment and country as factors. (NCT00412750)
Timeframe: Weeks 12 and 24

,,
Interventionlog 10 copies/ml (Least Squares Mean)
Week 12 (n= 37, 52, 50)Week 24 (n= 17, 48, 42)
LdT + PEG-INF-6.0569-6.9187
LdT Monotherapy-5.1658-5.9633
PEG-INF Monotherapy-1.8991-2.4513

[back to top]

Percentage of Participants Who Experienced Virologic Breakthrough at Weeks 48 and 52

The percentage of participants with Virologic breakthrough at Week 48 and 52 by treatment. For the subgroup of patients on treatment who achieve HBV DNA >= 1 log10 copies/mL reduction from baseline on 2 consecutive visits, Virologic Breakthrough is defined as HBV DNA >= 1 log10 copies/mL from nadir on two consecutive visits. (NCT00412750)
Timeframe: Weeks 48 and 52

,,
InterventionPercentage of participants (Number)
Virologic breakthrough Week 48Virologic breakthrough Week 52
LdT + PEG-INF0.00.0
LdT Monotherapy5.77.5
PEG-INF Monotherapy7.59.4

[back to top]

Percentage of Participants With HBV DNA Non-detectability and Alanine Aminotransferase (ALT) Normalization at Week 12 and Week 24 in Participants With HBeAg-positive Chronic Hepatitis B (CHB)

The percentage of participants who achieved HBV DNA non-detectability using the COBAS Amplicor HBV Monitor assay utilizing polymerase chain reaction (PCR) (threshold for detection 300 copies/mL) and Alanine aminotransferase (ALT) normalization defined as ALT within normal limits on two successive visits for a patient with an elevated ALT (>1.0 x upper limit normal) at baseline summarized at Weeks 12 and 24. (NCT00412750)
Timeframe: Weeks 12 and 24

,,
InterventionPercentage of participants (Number)
HBV DNA non-detectability Week 12 (n=37,52,50)ALT normalization Week 12 (n=37,52,50)HBV DNA non-detectability Week 24 (n=17,48,42)ALT normalization Week 24 (n=17,48,41)
LdT + PEG-INF13.513.570.611.8
LdT Monotherapy9.628.835.454.2
PEG-INF Monotherapy0.020.07.131.7

[back to top]

Percentage of Participants With Hepatitis B 'e' Antigen (HBeAg) Loss and HBeAg Seroconversion

HBeAg loss is defined as the loss of detectable serum HBeAg in a patient who was HBeAg positive at baseline. HBeAg seroconversion is defined as HBeAg loss with detectable Hepatitis B 'e' antibody (HBeAb). The efficacy was assessed for 18 weeks, 24 weeks, 48 weeks, 52 weeks and on treatment completion (TC). (NCT00412750)
Timeframe: Weeks 18, 24, 48, 52 and Treatment completion (TC)

,,
InterventionPercentage of participants (Number)
HBeAg loss Week 18 (n=28,51,45)HBeAg seroconversion Week 18 (n=28,51,45)HBeAg loss Week 24 (n=17,48,42)HBeAg seroconversion Week 24 (n=17,48,42)HBeAg loss Week 48 (n=0,19,12)HBeAg seroconversion Week 48 (n=0,19,12)HBeAg loss Week 52 (n=0,10,6)HBeAg seroconversion Week 52 (n=0,10,6)HBeAg loss TC (n=14,24,9)HBeAg seroconversion TC (n=14,24,9)
LdT + PEG-INF17.917.917.67.6NANANANA7.17.1
LdT Monotherapy7.87.86.34.236.836.850.050.029.225.0
PEG-INF Monotherapy8.98.911.911.925.025.016.716.733.333.3

[back to top]

"Percentage of Patients Who Achieve Hepatitis B e Antigen (HBeAg) Loss and HBeAg Seroconversion at Week 12"

"HBeAg loss is defined as the loss of detectable serum HBeAg in a patient who was HBeAg positive at baseline. HBeAg seroconversion is defined as HBeAg loss with detectable Hepatitis B 'e' antibody (HBeAb). HBeAg stands for hepatitis B e antigen. This antigen is a protein from the hepatitis B virus that circulates in infected blood when the virus is actively replicating. The presence of HBeAg suggests that the person is infectious and is able to spread the virus to other people." (NCT00805675)
Timeframe: Week 12

InterventionPercentage of Participants (Number)
Telbivudine 600 mg Monotherapy0
Tenofovir Disproxil Fumarate 300 mg Monotherapy0
Telbivudine 600 mg and Tenofovir 300 mg0

[back to top]

Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Week 12.

Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA. Serum HBV DNA determinations were performed at a central laboratory through use of the COBAS TaqMan™ HBV DNA assay (Roche Molecular Systems, Pleasanton, CA, USA) which utilized the Real-time polymerase chain reaction (PCR) method and automated extraction by Cobas Ampliprep (threshold for detection 12 IU/mL). The Screening serum HBV DNA values must be ≥ 7 log10 copies/mL by COBAS TaqMan™ HBV DNA assay. (NCT00805675)
Timeframe: Baseline, Week 12

Interventionlog10 copies/mL (Mean)
Telbivudine 600 mg Monotherapy-3.852
Tenofovir Disproxil Fumarate 300 mg Monotherapy-4.175
Telbivudine 600 mg and Tenofovir 300 mg-4.374

[back to top]

Characterization of Very Early Viral Kinetics Through Efficiency Factor of Blocking Virus Production.

"The underlying bi-phasic model of viral kinetics can be described as follows:~V(t) (1 )pI(t) cV(t) I(t) (1 ) (T I(t))V(t) I(t) where V denotes serum viral load, I productively infected cells, ε the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, η the efficiency factor of blocking de novo infection, β the de novo infection rate, Tg comprise allinfected and uninfected target cells, and δ the rate of infected cell loss" (NCT00805675)
Timeframe: Week 12

InterventionPercentage (Mean)
Telbivudine 600 mg Monotherapy98.8
Tenofovir Disproxil Fumarate 300 mg Monotherapy99.0
Telbivudine 600 mg and Tenofovir 300 mg99.1

[back to top]

Characterization of Very Early Viral Kinetics Through Estimated Viral Load

"The underlying bi-phasic model of viral kinetics can be described as follows:~V(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, ε the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, η the efficiency factor of blocking de novo infection, β the de novo infection rate, Tg comprise all infected and uninfected target cells, and δ the rate of infected cell loss" (NCT00805675)
Timeframe: Week 12

Interventionlog10 copies/ml (Mean)
Telbivudine 600 mg Monotherapy8.9
Tenofovir Disproxil Fumarate 300 mg Monotherapy8.7
Telbivudine 600 mg and Tenofovir 300 mg8.7

[back to top]

Characterization of Very Early Viral Kinetics Through Half-live of Free Virus

"The underlying bi-phasic model of viral kinetics can be described as follows:~V(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, ε the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, η the efficiency factor of blocking de novo infection, β the de novo infection rate, Tg comprise all infected and uninfected target cells, and δ the rate of infected cell loss" (NCT00805675)
Timeframe: Week 12

InterventionHours (Mean)
Telbivudine 600 mg Monotherapy18.1
Tenofovir Disproxil Fumarate 300 mg Monotherapy16.4
Telbivudine 600 mg and Tenofovir 300 mg18.9

[back to top]

Characterization of Very Early Viral Kinetics Through Viral Clearance

"The underlying bi-phasic model of viral kinetics can be described as follows:~V(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, ε the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, η the efficiency factor of blocking de novo infection, β the de novo infection rate, Tg comprise all infected and uninfected target cells, and δ the rate of infected cell loss" (NCT00805675)
Timeframe: Week 12

Interventionday^-1 (Mean)
Telbivudine 600 mg Monotherapy0.98
Tenofovir Disproxil Fumarate 300 mg Monotherapy1.19
Telbivudine 600 mg and Tenofovir 300 mg1.08

[back to top]

Percentage of Patients Who Are Polymerase Chain Reaction(PCR)Negative at Week 12

Polymerase Chain Reaction (PCR) Negative is defined as HBV DNA levels <25 copies/ml. (NCT00805675)
Timeframe: Week 12

InterventionPercentage of Participants (Number)
Telbivudine 600 mg Monotherapy0.0
Tenofovir Disproxil Fumarate 300 mg Monotherapy0.0
Telbivudine 600 mg and Tenofovir 300 mg0.0

[back to top]

Characterization of Very Early Viral Kinetics Through Rate of Infected Cell Loss

"The underlying bi-phasic model of viral kinetics can be described as follows:~V(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, ε the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, η the efficiency factor of blocking de novo infection, β the de novo infection rate, Tg comprise all infected and uninfected target cells, and δ the rate of infected cell loss" (NCT00805675)
Timeframe: Week 12

Interventionday^-1 (Mean)
Telbivudine 600 mg Monotherapy0.04
Tenofovir Disproxil Fumarate 300 mg Monotherapy0.06
Telbivudine 600 mg and Tenofovir 300 mg0.05

[back to top]

Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Weeks 2, 4 and 8.

Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA. Serum HBV DNA determinations were performed at a central laboratory through use of the COBAS TaqMan™ HBV DNA assay (Roche Molecular Systems, Pleasanton, CA, USA) which utilized the Real-time polymerase chain reaction (PCR) method and automated extraction by Cobas Ampliprep (threshold for detection 12 IU/mL). The Screening serum HBV DNA values must be ≥ 7 log10 copies/mL by COBAS TaqMan™ HBV DNA assay. (NCT00805675)
Timeframe: Baseline, Week 2, Week 4, Week 8

,,
Interventionlog10 copies/mL (Mean)
Week 2Week 4Week 8
Telbivudine 600 mg and Tenofovir 300 mg-2.689-3.225-3.845
Telbivudine 600 mg Monotherapy-2.657-2.985-3.474
Tenofovir Disproxil Fumarate 300 mg Monotherapy-2.541-3.060-3.621

[back to top]

HBV-DNA < 300 Copies/mL in 48 Weeks

(NCT00970216)
Timeframe: 48 weeks

Interventionparticipants (Number)
Chronic Hepatitis B79

[back to top]

eGFR Change From Baseline in Telbivudine Arm vs Tenofovir Arm Over the Course of the Study

eGFR changes were calculated using the Modification of Diet in Renal Disease (MDRD) formula: GFR = 186 x (sCr)^(-1.154) x (age)^-0.203 with Female: Multiply GFR by 0.742; Black: Multiply GFR by 1.210. sCr is Serum Creatinine in mg/dl (measured at each scheduled visit). Age in years at visit (=[sCr sample collection date -Date of birth]/365.25). Weight in kilograms, as measured at the visit or the closest previous visit Safety population. (NCT01379508)
Timeframe: Baseline, 24 weeks, 52 weeks, 104 weeks, 156 weeks

,,,,,
InterventionmL/min/1.73 m2 (Mean)
Week 24 change (97,22,119,108,11,119)Week 52 change(97,22,119,108,11,119)Week 104 change(97,22,119,108,11,119)Week 156 change(62,17,79,79,10,89)Baseline actual(98,22,120,109,11,120)Week 24 actual(97,22,119,108,11,119)Week 52 actual(97,22,119,108,11,119)Week 104 actual (97,22,119,108,11,119)Week 156 actual(62,17,79,79,10,89)
LdT Mono at Week 241.435.185.198.0794.7196.43100.18100.20101.33
LdT Overall-1.072.963.163.9997.4796.67100.70100.90101.20
LdT+TDF at Week 24-12.06-6.80-5.77-10.89109.7997.73102.99104.02100.70
TDF + LdT at Week 24-7.17-8.39-8.69-6.6794.5087.3386.1285.8187.93
TDF Mono at Week 24-2.41-2.70-3.83-5.3495.9193.6193.3292.1988.83
TDF Overall-2.85-3.22-4.28-5.4995.7893.0392.6691.6088.73

[back to top]

Percentage of Participants Achieving HBV DNA < 300 Copies/mL (51 IU/mL) at Week 52 (rITT Population) -

"The primary objective of the study is to compare the efficacy of Roadmap-Concept-based telbivudine treatment versus Roadmap-Concept-based tenofovir treatment in HBeAg-negative CHB patients. The rate of HBV DNA < 300 copies/mL (51 IU/mL) at week 52 will be used for the comparison of the efficacy. The hypothesis is that the aggregated rate of HBV DNA < 300 copies/mL (51 IU/mL) at week 52 of Telbivudine (ARM 1) is non-inferior to Tenofovir (ARM 2). For the treating missing as failure analysis, patients who came for their primary endpoint Week 52 visit within the ± 7-day window but not on the exact designated day of the visit were treated as missing data." (NCT01379508)
Timeframe: week 52

,
Interventionpercentage of participants (Number)
Missing DNA data at Wk 52=failureImputing +/- 7 days DNA for Wk 52Imputing LOCF DNA for Wk 52Imputing within +28d DNA for Wk 52
LdT Overall91.091.995.492.7
TDF Overall95.095.099.295.0

[back to top]

Percentage of Participants Achieving Secondary Efficacy Endpoints at Week 156 (mITT)

To assess the antiviral efficacy, as evaluated by the percentage of patients achieving HBV DNA <300 copies/mL (51 IU/mL) at Week156, ALT normalization, HBsAg loss, development of HBsAg conversion , cumulative tx emergent resistance, HBV DNA <300 copies/mL with HBV DNA <7 log at Baseline (NCT01379508)
Timeframe: 156 weeks

,,,,,
Interventionpercentage of participants (Number)
HBV DNA < 300 Week 156HBV DNA < 300 Wk156 LOCFALT normalization Wk 156ALT normalization Wk 156 LOCFHBSAg loss/ seroconversionCum VB Wk104-156 LOCFCum VB BL to Wk 156 LOCFCum tx emerg resist Week 156 LOCFHBV DNA < 300 Wk156 <7 log at BLHBV DNA <300 Wk156 <7 log LOCFCum tx-emerg resist Wk156 <7log LOCF
LdT Mono at Week 2417.788.714.385.7016.121.014.017.688.28.7
LdT Overall16.591.112.088.0012.716.510.816.788.98.2
LdT+TDF at Week 2411.8100.06.793.300000100.00.0
TDF + LdT at Week 2420.0100.028.685.7000050.0100.00.0
TDF Mono at Week 2413.9100.010.586.801.31.3011.7100.00.0
TDF Overall14.6100.0013.386.701.11.1012.9100.00.0

[back to top]

Percentage of Patients Achieving Secondary Efficacy Endpoints (rITT)

To assess the antiviral efficacy, as evaluated by the percentage of patients achieving HBV DNA <300 copies/mL (51 IU/mL), ALT normalization, HBsAg loss, HBsAg conversion, virologic breakthrough (VB) at study visit, cumulative VB by study defined study period, cumulative treatment-emergent resistance (NCT01379508)
Timeframe: week 24, 52, 104

,,,,,
Interventionpercentage of particiipants (Number)
HBV DNA <300 Week 24HBV DNA <300 Week 104HBV DNA <300 Week 24 LOCFHBV DNA <300 Wk104 LOCFALT Normalization Wk 52ALT Normalization Week 104ALT Normalization Wk 52 LOCFALT Normalization Wk 104 LOCFHBsAg loss Week 52HBsAg loss Week 104HBsAg conversion Week 52HBsAg conversion Week 104Cum virol break BaseL to Wk 24Cum virol break Wk 24 to Wk 52Cum virol break Wk 52 to Wk 104Cum virol break BaseLto Wk 104Cum vir break BL to Wk24 LOCFCum virol break Wk 24 to Wk 52 LOCFCum virol break Wk52-Wk104 LOCFCum virol break BLto Wk 104 LOCFCum tx emergent resistance Wk 52Ccum tx emergent resistance Wk 104Cum tx emergent resist Wk52 LOCFCum tx emergent resist Wk 104 LOCF<7 log at BL HBV DNA <300 Wk52<7 log HBV DNA <300 Wk104<7 log HBV DNA <300 Wk 52 LOCF<7 log HBV DNA <300 Wk 104 LOCF
LdT Mono at Week 2498.969.6100.092.484.070.088.092.0000003.312.014.103.312.014.13.39.23.39.293.468.497.492.1
LdT Overall80.570.881.493.883.870.686.889.700000.92.79.712.40.92.79.712.42.77.42.77.492.567.597.592.5
LdT+TDF at Week 240.076.20100.083.372.283.383.300004.8004.84.8004.8000075.050.0100.0100.0
TDF + LdT at Week 24081.80100.085.785.785.785.70000000000000000100.066.7100.0100.0
TDF Mono at Week 2499.174.5100.099.182.561.487.786.00000001.91.9001.91.9000095.076.3100.098.8
TDF Overall89.775.290.699.182.864.187.585.90000001.71.7001.71.7000095.275.9100.098.8

[back to top]

Number of Patients Achieving Serum HBV DNA Level of <300 Copies/mL (51 IU/mL) at Week 24

The primary objective of this study was to demonstrate the antiviral efficacy of telbivudine compared to placebo in pediatric patients (2- < 18 years) by determining the percentage of patients achieving serum HBV DNA level of <300 copies/mL (51 IU/mL) at Week 24. (NCT02058108)
Timeframe: Week 24

InterventionParticipants (Count of Participants)
Telbivudine5
Placebo1

[back to top]

Number of Participants With On-Treatments Adverse Events, Serious Adverse Events, and Death

"Evaluation of the safety and tolerability of Telbivudine defined by AEs, SAEs, adverse events of special interest (AESI) (including muscle related events) and death; laboratory evaluations specifically on-treatment and post-treatment ALT flares, incidence and clinical significance of CK elevations; growth and development (linear growth and sexual maturation); development of liver decompensation and/or HCC.~Only descriptive analysis performed." (NCT02058108)
Timeframe: From first dose of study treatment to 30 days after last dose of study treatment, up to 112 weeks

,
InterventionParticipants (Count of Participants)
On-treatment Adverse Event (AEs)On-treatment Serious Adverse Event (SAEs)On-treatment Deaths
Placebo400
Telbivudine2000

[back to top]

Number of Patients Achieving a Composite Endpoints (HBV DNA < 300 Copies/mL (51 IU/mL), ALT Normalization and HBeAg Seroconversion) at Week 52 and 104

"The proportion of patients achieving composite endpoints at Week 52 and 104 was to be evaluated by the proportion of patients achieving: a) HBV DNA <300 copies/mL (51 IU/mL); b) ALT normalization and HBeAg seroconversion for HBeAg positive patients only; c) HBV DNA <300 copies/mL (51 IU/mL) and ALT normalization for HBeAg negative patients.~Due to early termination of the study and limited number of enrolled patients on track to complete 52 weeks of participation (8 patients overall), only descriptive analysis performed at Week 52 and Week 104." (NCT02058108)
Timeframe: Week 52, Week 104

InterventionParticipants (Count of Participants)
Week 52
Placebo0

[back to top]

Number of Patients Achieving a Composite Endpoints (HBV DNA < 300 Copies/mL (51 IU/mL), ALT Normalization and HBeAg Seroconversion) at Week 52 and 104

"The proportion of patients achieving composite endpoints at Week 52 and 104 was to be evaluated by the proportion of patients achieving: a) HBV DNA <300 copies/mL (51 IU/mL); b) ALT normalization and HBeAg seroconversion for HBeAg positive patients only; c) HBV DNA <300 copies/mL (51 IU/mL) and ALT normalization for HBeAg negative patients.~Due to early termination of the study and limited number of enrolled patients on track to complete 52 weeks of participation (8 patients overall), only descriptive analysis performed at Week 52 and Week 104." (NCT02058108)
Timeframe: Week 52, Week 104

InterventionParticipants (Count of Participants)
Week 52Week 104
Telbivudine11

[back to top]

Number of Patients Achieving Cumulative Rate of Virological Breakthrough (VB) at Week 52 and 104

"The assessment of virological breakthrough (VB) was to be evaluated by: a) the cumulative rate of patients with confirmed VB at Week 52 and Week 104; b) the time to VB.~Due to early termination of the study and limited number of enrolled patients on track to complete 52 weeks of participation (8 patients overall), only descriptive analysis performed at Week 52 and Week 104." (NCT02058108)
Timeframe: Week 52, Week 104

,
InterventionParticipants (Count of Participants)
Week 52Week 104
Placebo00
Telbivudine11

[back to top]

Number of Patients Achieving HBV DNA< 300 Copies/mL (51 IU/mL) at Week 52 and Week 104

"The antiviral efficacy at Weeks 52 and 104 was to be evaluated by: a) the proportion of patients achieving HBV DNA <300 copies/mL (51 IU/mL) at Week 52 and Week 104; b) the proportion of patients achieving HBV DNA < Lower Limit of Quantification (LLOQ), <1000 copies/ml (or 200 IU/mL), <10,000 copies/ml (or 2 000 IU/mL) and ≥10,000 copies/mL (or 2 000 IU/mL) at Week 24, 52 and 104; c) the proportion of patients achieving Serum HBV DNA reduction from baseline; d) the time to achieve HBV DNA <300 copies/mL (51 IU/mL); e) the proportion of patients with Primary non-response.~Due to early termination of the study and limited number of enrolled patients on track to complete 52 weeks of participation (8 patients overall), only descriptive analysis performed at Week 52 and Week 104." (NCT02058108)
Timeframe: Week 52, Week 104

InterventionParticipants (Count of Participants)
Week 52
Placebo0

[back to top]

Number of Patients Achieving HBV DNA< 300 Copies/mL (51 IU/mL) at Week 52 and Week 104

"The antiviral efficacy at Weeks 52 and 104 was to be evaluated by: a) the proportion of patients achieving HBV DNA <300 copies/mL (51 IU/mL) at Week 52 and Week 104; b) the proportion of patients achieving HBV DNA < Lower Limit of Quantification (LLOQ), <1000 copies/ml (or 200 IU/mL), <10,000 copies/ml (or 2 000 IU/mL) and ≥10,000 copies/mL (or 2 000 IU/mL) at Week 24, 52 and 104; c) the proportion of patients achieving Serum HBV DNA reduction from baseline; d) the time to achieve HBV DNA <300 copies/mL (51 IU/mL); e) the proportion of patients with Primary non-response.~Due to early termination of the study and limited number of enrolled patients on track to complete 52 weeks of participation (8 patients overall), only descriptive analysis performed at Week 52 and Week 104." (NCT02058108)
Timeframe: Week 52, Week 104

InterventionParticipants (Count of Participants)
Week 52Week 104
Telbivudine32

[back to top]

Number of Participants With Treatment Emergent Genotypic Resistance Associated With VB, or in Patients With HBV DNA≥300 Copies/mL (51 IU/mL) at Week 24 and Discontinued From the Study

Assessment of the presence of treatment emergent genotypic resistance (confirmed by genotypic sequencing) associated with virological breakthrough over the study period, or in patients with HBV DNA≥300 copies/mL (51 IU/mL) at Week 24 and discontinued from the study treatment (or at discontinuation if prior to Week 24 for subjects with at least 16 weeks of LDT treatment) (NCT02058108)
Timeframe: Week 24

,
InterventionParticipants (Count of Participants)
Cumulative virological breakthroughCumulative treatment emergent genotypic resistance
Placebo00
Telbivudine01

[back to top]

Number of Patients Whose Baseline ALTs Were Abnormal and Subsequently Normalized at Week 24, 52 and 104

"The biochemical response at Weeks 24, 52 and 104 was to be evaluated by the proportion of patients whose baseline ALTs were abnormal (defined as ALT >1 x Upper Limit of Normal [ULN]) and subsequently normalized.~Due to early termination of the study and limited number of enrolled patients on track to complete 52 weeks of participation (8 patients overall), only descriptive analysis performed at Week 52 and Week 104." (NCT02058108)
Timeframe: Week 24, Week 52, Week 104

InterventionParticipants (Count of Participants)
Week 24Week 52Week 104
Telbivudine1212

[back to top]

Number of Patients With HBeAg Loss, HBeAg Seroconversion at Week 24, 52 and 104

"The serological response at Weeks 24, 52 and 104 was to be evaluated by: a) the proportion of HBeAg positive patients at baseline who subsequently have HBeAg loss and HBeAg seroconversion (defined as loss of HBeAg with detectable HBeAb); b) the proportion of HBsAg positive patients at baseline who subsequently have HBsAg loss and HBsAg seroconversion (defined as loss of HBsAg with detectable HBsAb).~Due to early termination of the study and limited number of enrolled patients on track to complete 52 weeks of participation (8 patients overall), only descriptive analysis performed at Week 52 and Week 104." (NCT02058108)
Timeframe: Week 24, Week 52, Week 104

InterventionParticipants (Count of Participants)
HBeAg loss at Week 24HBeAg seroconversion at Week 24HBeAg loss at Week 52HBeAg seroconversion at Week 52
Placebo0000

[back to top]

Number of Patients With HBeAg Loss, HBeAg Seroconversion at Week 24, 52 and 104

"The serological response at Weeks 24, 52 and 104 was to be evaluated by: a) the proportion of HBeAg positive patients at baseline who subsequently have HBeAg loss and HBeAg seroconversion (defined as loss of HBeAg with detectable HBeAb); b) the proportion of HBsAg positive patients at baseline who subsequently have HBsAg loss and HBsAg seroconversion (defined as loss of HBsAg with detectable HBsAb).~Due to early termination of the study and limited number of enrolled patients on track to complete 52 weeks of participation (8 patients overall), only descriptive analysis performed at Week 52 and Week 104." (NCT02058108)
Timeframe: Week 24, Week 52, Week 104

InterventionParticipants (Count of Participants)
HBeAg loss at Week 24HBeAg seroconversion at Week 24HBeAg loss at Week 52HBeAg seroconversion at Week 52HBeAg loss at Week 104HBeAg seroconversion at Week 104
Telbivudine111111

[back to top]

Number of Patients With HBsAg Loss, HBsAg Seroconversion at Week 24, 52 and 104

"The serological response at Weeks 24, 52 and 104 was to be evaluated by: a) the proportion of HBeAg positive patients at baseline who subsequently have HBeAg loss and HBeAg seroconversion (defined as loss of HBeAg with detectable HBeAb); b) the proportion of HBsAg positive patients at baseline who subsequently have HBsAg loss and HBsAg seroconversion (defined as loss of HBsAg with detectable HBsAb).~Due to early termination of the study and limited number of enrolled patients on track to complete 52 weeks of participation (8 patients overall), only descriptive analysis performed at Week 52 and Week 104." (NCT02058108)
Timeframe: Week 24, Week 52, Week 104

InterventionParticipants (Count of Participants)
HBsAg loss at Week 24HBsAg seroconversion at Week 24HBsAg loss at Week 52HBsAg seroconversion at Week 52
Placebo0000

[back to top]

Number of Patients With HBsAg Loss, HBsAg Seroconversion at Week 24, 52 and 104

"The serological response at Weeks 24, 52 and 104 was to be evaluated by: a) the proportion of HBeAg positive patients at baseline who subsequently have HBeAg loss and HBeAg seroconversion (defined as loss of HBeAg with detectable HBeAb); b) the proportion of HBsAg positive patients at baseline who subsequently have HBsAg loss and HBsAg seroconversion (defined as loss of HBsAg with detectable HBsAb).~Due to early termination of the study and limited number of enrolled patients on track to complete 52 weeks of participation (8 patients overall), only descriptive analysis performed at Week 52 and Week 104." (NCT02058108)
Timeframe: Week 24, Week 52, Week 104

InterventionParticipants (Count of Participants)
HBsAg loss at Week 24HBsAg seroconversion at Week 24HBsAg loss at Week 52HBsAg seroconversion at Week 52HBsAg loss at Week 104HBsAg seroconversion at Week 104
Telbivudine100000

[back to top]

Number of Patients Whose Baseline ALTs Were Abnormal and Subsequently Normalized at Week 24, 52 and 104

"The biochemical response at Weeks 24, 52 and 104 was to be evaluated by the proportion of patients whose baseline ALTs were abnormal (defined as ALT >1 x Upper Limit of Normal [ULN]) and subsequently normalized.~Due to early termination of the study and limited number of enrolled patients on track to complete 52 weeks of participation (8 patients overall), only descriptive analysis performed at Week 52 and Week 104." (NCT02058108)
Timeframe: Week 24, Week 52, Week 104

InterventionParticipants (Count of Participants)
Week 24Week 52
Placebo01

[back to top]